Underuse and overuse of colonoscopy among survivors of colorectal cancer by Salz, Talya
  
Underuse and overuse of colonoscopy among survivors of colorectal cancer 
 
 
Talya Salz 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel 
Hill in partial fulfillment of the requirements for the degree of Doctorate of Philosophy 
in the Department of Health Policy and Management. 
 
 
Chapel Hill 
2008 
 
Approved by: 
Dr. Morris Weinberger 
Dr. Andrea Biddle 
Dr. Noel Brewer 
Dr. Robert Sandler 
Dr. Bryan Weiner 
 ii 
 
 
 
ABSTRACT 
Talya Salz 
Underuse and overuse of colonoscopy among survivors of colorectal cancer 
(Under the direction of Morris Weinberger, PhD) 
 
Survivors of colorectal cancer are at increased risk for both a local recurrence 
of their cancer and a second primary colorectal cancer.  Because of this elevated 
risk, clinical practice guidelines recommend routine surveillance with colonoscopy.  
However, a substantial proportion of colorectal cancer survivors either underuse or 
overuse colorectal cancer surveillance.  The causes of nonadherence are not clear, 
although some sociodemographic and clinical correlates of underuse have been 
identified.  
This dissertation expands on previous studies of surveillance colonoscopy by 
using a recent, diverse cohort of survivors; investigating the role of primary care in 
ongoing surveillance; and extending the Health Belief Model to the study of 
colorectal cancer survivors to identify potentially modifiable factors that are 
associated with intentions to undergo colonoscopy.  Data came from colorectal 
cancer survivors in the Cancer Care Outcomes Research and Surveillance, a 
national population-based cohort study.   
The first of the three papers investigated correlates of colonoscopy use by 14 
months after surgery using medical records and patient interviews from the entire 
 iii 
cohort.  The second and third papers used medical records and interviews from 
participants in North Carolina who participated in an interview 4 years after 
diagnosis.  The second paper measured the rates and correlates of both underuse 
and overuse of colonoscopy in the 4 years after diagnosis.  The third paper 
investigated the association of health beliefs and intentions to undergo colonoscopy 
in the future. 
Results showed that colonoscopy use by 14 months was low (40%), and 
colonoscopy use varied by important clinical factors; rectal cancer survivors and 
survivors with more severe comorbidities were less likely to undergo colonoscopies 
in 14 months.  Use of primary care and other health services were correlated with 
colonoscopy use.  By 4 years, the rates of self-reported underuse and overuse were 
18% and 21%, respectively, and only severity of comorbidities predicted underuse.  
Perceived likelihood of getting colorectal cancer, barriers to colorectal cancer, and 
recommendations from certain healthcare providers were associated with greater 
intentions to undergo colonoscopy in the future.  This dissertation identified 
vulnerable subgroups of colorectal cancer survivors and important modifiable targets 
for interventions that may improve adherence to surveillance colonoscopy 
guidelines. 
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I.  INTRODUCTION 
 
Colorectal cancer survivors are a large and growing group, with unique 
health concerns.  Colorectal cancer survivors are at elevated risk for recurrences 
and second primary colorectal cancers.  Because ongoing surveillance may 
reduce mortality from colorectal cancer, clinical practice guidelines recommend 
ongoing colorectal surveillance using colonoscopy for colorectal cancer 
survivors.  However, prior studies have shown that many colorectal cancer 
survivors get colonoscopies late or not at all, and, surprisingly, another subset of 
colorectal cancer survivors get colonoscopies too frequently.  The goals of this 
dissertation are to identify which survivors overuse and underuse surveillance 
colonoscopy to detect colorectal cancer.  Further, in order to facilitate the 
development of interventions to improve adherence to guidelines, another goal is 
to understand the beliefs survivors hold about undergoing colonoscopies and 
preventing colorectal cancer.  Guided by the Health Belief Model (HBM), health 
beliefs are examined as predictors of intentions to undergo colonoscopy in the 
future. 
Predictors of underuse of colonoscopy have been studied, but prior 
studies have been limited by their use of older data (corresponding to earlier 
colonoscopy guidelines), administrative data, or restricted groups of survivors 
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(older or insured).  They also did not distinguish the predictors of underuse and 
overuse of colonoscopy.  This dissertation used recent data from medical records 
and survivor interviews to identify survivor factors that are associated with both 
the underuse and overuse of colonoscopy among colorectal cancer survivors.  
Further, in response to a report by the Institute of Medicine that proposed that 
survivors do not receive adequate preventive services due to poor continuity of 
care, this dissertation examined whether primary care use was associated with 
colonoscopy use.  Finally, although the HBM has been extensively employed to 
understand colorectal cancer screening behavior among the general population, 
this dissertation extends the HBM to colonoscopy use among colorectal cancer 
survivors.  Specifically, it investigates the association of health beliefs with 
intentions to receive colonoscopy in the future.   
I have chosen the 3 paper option for my dissertation.  Chapter 2 presents 
background on colorectal cancer, survivorship, surveillance guidelines, 
information about overuse and underuse of colorectal cancer, and the theoretical 
framework for the 3 studies in this dissertation.  The aims and hypotheses of the 
dissertation are presented as well.   
Chapter 3 presents an overview of the research design and methods of 
the Cancer Care Outcomes and Research Study (CanCORS), the project from 
which data for my dissertation come.  In particular, I will describe both the 
national cohort used in Paper 1 and the North Carolina cohort used in Papers 2 
and 3.  This chapter describes the measures used and an overview of my 
analytic plan. 
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Chapter 4 (Paper 1) describes factors associated with the overuse and 
underuse of screening colonoscopy among colorectal cancer survivors.  This 
manuscript identifies important clinical, sociodemographic, and health services 
use predictors of colonoscopy use, as determined by survivor medical records 
and interviews.  Chapter 5 (Paper 2) , evaluates the extent of underuse and 
overuse of colonoscopy four years after diagnosis.  It also investigates 
determinants of both underuse and overuse of surveillance colonoscopy.  
Chapter 6 (Paper 3) assesses the health beliefs of survivors in relation to 
intentions to undergo colonoscopy use in the future, with the aim of identifying 
modifiable targets for interventions to improve adherence to surveillance 
colonoscopy.   
Finally, chapter 7 summarizes findings from all three studies and 
examines their contribution to our understanding of colonoscopy use among 
colorectal cancer survivors.  It discusses the implications of the findings for 
health systems, providers, and survivors of colorectal cancer, and explore 
directions for future research. 
  
 
 
II.  BACKGROUND AND SIGNIFICANCE 
 
2.1  Colorectal cancer survivorship 
There are an estimated one million colorectal cancer survivors in the 
United States.1  Because the overall five-year adjusted survival rate for colorectal 
cancer is 64%, and 90% for people with localized disease, most people with 
colorectal cancer will live beyond acute treatment for their disease.2, 3   
Along with the benefits of surviving beyond treatment, colorectal cancer 
survivors face unique ongoing health risks.  Specifically, colorectal cancer 
survivors are at increased risk for both local recurrence and second primary 
colorectal cancer.  Up to 40% of local or locally advanced colorectal cancer will 
recur in a patient’s lifetime.2  It is estimated that local recurrence occurs in 
approximately 2-4% of colon cancer patients; the estimate for rectal cancer is 
approximately 10 times higher.4  Recurrence most frequently occurs within five 
years of diagnosis.1  colorectal cancer survivors are also at elevated risk for a 
second primary cancer compared to either the general population or those with 
adenomatous polyps.5  Five years after diagnosis, 1.5% of colorectal cancer 
survivors will have a second primary colorectal cancer,2  and the cumulative 
incidence for a second primary over 25 years is 3.2%.1  The standardized 
incidence ratio of 1.36 indicates that there is a 36% increase in risk of colorectal 
cancer for colorectal survivors compared to non-affected individuals.  Put another 
 5 
way, the excess risk of a second colorectal cancer is 129.5 cases per 100,000 
people.6   
 
2.2  Addressing ongoing risks 
Given the risk of both local recurrences and second primary colorectal 
cancers, clinical practice guidelines recommend ongoing surveillance.  The 
purpose of surveillance is to identify and remove precancerous polyps and to 
identify local recurrences and second colorectal cancers at a more easily 
treatable or curable stage. Thus, “surveillance” refers to testing among people 
with a history of cancer, whereas “screening” refers to testing among 
asymptomatic people without a history of cancer.   
Different groups have put forth conflicting guidelines for colorectal cancer 
surveillance with colonoscopy, and guidelines have changed over time (Table 
2.1).  Notably, guidelines were inconsistent regarding the recommended 
surveillance interval (e.g., colonoscopy 1 versus 3 years after resection).7, 8  The 
most recent guidelines, published in 2006, represents a consensus of multiple 
agencies in the U.S. regarding routine surveillance colonoscopies for colorectal 
cancer. 2      
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Recently, the American Cancer Society and the U.S. Multisociety Task Force 
on Colorectal Cancer published guidelines for surveillance after colorectal cancer 
resection.  In brief, the new guidelines recommend surveillance via colonoscopy 
perioperatively (before surgery if possible), 1 and 3 years after surgery, and then 
every 5 years for asymptomatic people.4   The guidelines favored colonoscopy over 
barium enemas, fecal occult blood testing (FOBT), and CT colonography.  
Sigmoidoscopy is recommended in addition to colonoscopy for survivors of rectal 
cancer, and it is a necessary substitute for colonoscopy for patients who had a total 
colectomy, which was performed in 1.9% of colon cancer patients nationally in 
2004.18  These guidelines apply to all stages of colorectal cancer resected for cure.  
Unlike other cancers, stage IV colorectal cancer may be curable if there is an 
isolated liver or lung metastasis.4 
 
2.3  Adherence to colonoscopy guidelines 
Failing to undergo colonoscopies at the recommended intervals may result in 
poorer clinical outcomes.  Underuse of routine surveillance colonoscopy may result 
in tumors being detected only after they become symptomatic, at which point they 
may be more difficult to treat.  Evidence suggests that many survivors are not 
receiving their first surveillance on time or at all.   Estimates of receipt within 18 
months of surgery range from 54% to 61%, with the most recent and comprehensive 
estimate at 54%.7, 8, 19, 20  Moreover, only 65% to 70% colorectal cancer survivors 
received at least one surveillance colonoscopy within three years, and 77% to 83% 
within five years, of surgery.7, 19-21   
 8 
Overuse of colonoscopy can also result in poor outcomes.  If little clinical 
benefit arises from more frequent colonoscopies, the harms (e.g., bleeding and 
tearing, morbidity and costs of false positive results) may outweigh the benefits.  In 
addition, from a resources perspective, overuse of colonoscopy may strain the 
capacity of colonoscopy providers, and longer wait times may delay care for patients 
who need it most.  There appears to be overuse of colorectal cancer surveillance.  
Among survivors who received a first colonoscopy after surgery, one study 
estimated that 55% received a second colonoscopy within five years; however, the 
median time between the first two colonoscopies was 13.4 months, an interval 
shorter than any guideline recommends.19  Another study found that 62% of those 
receiving a first colonoscopy had another colonoscopy within 18 months (median 
interval = 13.8 months).8  A study of using SEER-Medicare data found that after one 
year of surgery, 11% of people had colonoscopies annually or more frequently.21 
 
2.4  Understanding nonadherence 
Prior studies have assessed some clinical and demographic correlates of 
underuse and overuse of surveillance colonoscopy.  Clinically, survivors of rectal 
cancer are less likely than survivors of colon cancer to receive surveillance 
colonoscopy.2, 19, 20, 22-24  This may be because rectal cancer patients are more likely 
to get other surveillance exams, such as sigmoidoscopy,23 although evidence for this 
is mixed.24  Colonoscopy use also appears to vary by demographic characteristics of 
survivors as well.  Higher surveillance colonoscopy rates have been found among 
younger survivors and those with fewer comorbidities.20, 21, 23, 24  Survivors with 
 9 
higher incomes may be more likely than those with lower incomes to receive post-
surgical colon exams.19, 20  One study found that married survivors are more likely to 
receive colonoscopies than their counterparts.20  White survivors have been shown 
to be more likely to receive colonoscopies than black survivors,20, 22, 24, 25 although 
evidence is insconsistent.19, 23  Demographic factors may affect utilization by 
determining whether the person has access to high quality ongoing care and 
whether they can afford that care.  To the extent that colonoscopy is physician-
driven, it is possible that physicians aim to prevent cancer at all costs, but provide 
frequent colonoscopies only to better insured patients.   
Some of this nonadherence may actually be appropriate, such as if sicker 
patients are too frail to undergo the procedure, or if older or sicker patients would not 
have a long enough life expectancy to benefit from early detection.  In cases where 
nonadherent care is more appropriate for the survivors’ situation, nonadherence 
should not be considered underuse or overuse.  For simplicity, this dissertation will 
use the terms underuse and overuse to describe nonadherence to guidelines, but 
findings of nonadherence which may not be examples of worse care will be explicitly 
addressed in the discussion sections of each paper. 
 
2.5  Gaps in our understanding of nonadherence 
There exist several limitations of prior studies of overuse and underuse of 
surveillance colonoscopy among colorectal cancer survivors.  First, all studies of 
survivor factors and surveillance have focused on insured patients or patients in 
limited geographic regions.8, 19, 20, 22-25  Some studies investigated only Medicare 
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patients, who are older and at least partially insured.22, 23, 25   Survivor characteristics 
related to colonoscopy use have not been studied in a population-based setting that 
includes uninsured and younger patients.   
Second, important characteristics of survivors have not been addressed in 
earlier studies.  Specifically, the receipt of ongoing primary care after treatment for 
colorectal cancer has not been evaluated in relation to whether survivors get 
appropriate surveillance.  An Institute of Medicine (IOM) report found that colorectal 
cancer survivors have unique medical and psychosocial risks that require ongoing 
attention.  At the same time, the shift from cancer treatment to survivorship care may 
be difficult, and many survivors are “lost in transition.”2  One study found that 
Medicare-eligible 5-year colorectal cancer survivors generally received less 
recommended care than matched non-affected controls.26  This included 
management of chronic conditions, preventive care, and receipt of necessary acute 
interventions.   The same study found that survivors who saw a primary care 
physician were more likely to receive recommended care than patients seeing an 
oncologist, although patients who saw both were most likely to get recommended 
care.  No published study has investigated whether seeing a primary care provider is 
associated with increased surveillance among colorectal cancer survivors. 
Finally, prior studies have identified clinical and demographic characteristics 
of survivors who are more at risk for nonadherence to colonoscopy guidelines, but 
for the most part, these characteristics are immutable and may not provide insights 
on the nature of potential strategies to increase surveillance.  If the goal of 
understanding surveillance patterns is to improve adherence, it may be useful to 
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understand survivors’ attitudes and beliefs about colorectal cancer surveillance that 
may be the target of interventions directed at patients, providers, and/or health care 
systems. 
The first and second of these gaps can be addressed by using a rich, diverse 
data set that includes indicators of primary care use, which will be described in more 
detail in the methods section.  The third gap requires a new approach to 
characterize survivors’ beliefs about colonoscopy and colorectal cancer, and how 
these beliefs relate to colonoscopy use. 
 
2.6  Applying new concepts to understanding survivor behavior 
The Health Belief Model (HBM) is a useful framework for identifying attitudes 
and beliefs that may contribute to engaging in preventive health activities.  The HBM 
posits that individuals engage in health-promoting behaviors because they expect 
their actions to help them to avoid the threat of disease.27  The level of threat is 
established by individuals’ perception of likelihood of the disease (also known as 
perceived risk or perceived susceptibility) and perceptions of severity of the disease.  
Perceived benefits and barriers to taking action, as well as cues to take action, self-
efficacy, and other demographic and background factors all contribute to the 
person’s decision to engage in the health promoting behavior. 
Reviews of the HBM generally demonstrate its predictive utility.  A meta-
analysis of the HBM in 234 studies of adults found the vast majority of studies used 
an incomplete set of HBM constructs (or health beliefs).  Still, across all studies, 
perceived risk, perceived severity, and benefits each were positively and statistically 
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significantly correlated with behavioral outcomes. Perceived barriers were negatively 
and statistically significantly correlated with behavioral outcome.28, 29  A more recent 
systematic review of the HBM in studies explaining breast cancer screening found 
that each component of the model predicted screening behavior, but the magnitude 
of effects and overall variance explained differed significantly.30  The authors noted 
that the studies used widely varying measures, included different subsets of HBM 
components, and used different types of outcome measures (such as past 
adherence to mammography or intentions to have a mammogram in the future).  
These reviews together suggest that HBM has predictive validity, although the 
widely varying quality of studies conducted makes any strong conclusions difficult. 
In the context of colorectal cancer survivors’ use of colonoscopy, the HBM 
predicts that the perceived likelihood and severity of colorectal cancer contribute to 
whether or not a survivor undergoes colonoscopy.  In addition, the model predicts 
that survivors balance the benefits of colonoscopy (e.g., detecting colorectal cancer 
at a treatable stage) with the perceived barriers to colonoscopy (e.g., pain, cost), 
and factor in any cues to action (e.g., a referral from a doctor) and their perception of 
whether they could get colonoscopy if they so chose.  Knowledge of how cognitive 
variables influence colonoscopy surveillance among colorectal cancer survivors 
could help guide the development of interventions to correct underuse or overuse of 
surveillance.  However, no published studies have tested the association of health 
beliefs and surveillance colonoscopy among colorectal cancer survivors.   
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2.7  Conceptual Model 
The HBM has been adapted for this dissertation in two ways.  First, perceived 
severity of colorectal cancer was not assessed.  This is because previous studies 
have found a ceiling effect for perceived severity in the context of colorectal cancer 
screening.31, 32  This ceiling effect is likely to be even more pronounced among 
survivors of colorectal cancer. 
Second, instead of colonoscopy use as the outcome, this dissertation uses 
intention to have a colonoscopy in the future as an outcome.  Many previous studies 
of the HBM are cross-sectional and, as such, can not evaluate the influence of HBM 
constructs on later behavior.  However, intention to engage in a behavior, such as 
colonoscopy, has been used in many cross-sectional studies that employ an HBM 
framework.  Studies of predictors of screening colonoscopy have used intention 
measures as outcome variables31, 33, as have studies of screening mammography.30   
The relationship between intention and behavior has been studied extensively, and 
Sheeran conducted a meta-analysis of 10 meta-analyses of the relationship between 
intentions and health behaviors.34  He found that intentions strongly predict 
behaviors across studies, with a sample-weighted correlation coefficient of 0.53.  In 
addition, the relationship between the two was strengthened when intention 
measures were phrased as expectations.  For example, using measures of “how 
likely” an individual is to engage in a behavior predicted behavior more strongly than 
measures of whether a person intends to engage in this behavior.34  Expectations 
may be more proximal to behavior, because perceived barriers may mediate 
between intentions and behaviors.  In addition, a person’s desire to engage in a 
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behavior may be related to behavior.  Although intention is an imperfect measure of 
future behavior, these studies show that intention, as well as expectations and 
desires, are strongly correlated with behavior. 
The following conceptual model (Figure 2.1), guided by the HBM, shows the 
hypothesized factors relating to colonoscopy use among survivors of colorectal 
cancer.  The numbers in circles show the Aim being investigated by that relationship.  
(Aims will be described later in this chapter.) 
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2.8  Health beliefs and screening colonoscopy 
Although surveillance colonoscopy among colorectal cancer survivors has not 
been studied within the framework of the HBM, health beliefs have been used to 
study colorectal cancer screening among asymptomatic adults in the general 
population.35-40    Because surveillance colonoscopy involves testing for the same 
disease (in a different population), findings from these studies can inform our 
understanding of the role of health beliefs in receipt of surveillance colonoscopy 
among colorectal cancer survivors.  One caveat in extending lessons from screening 
to surveillance is that there are many modalities of screening.  Colonoscopy is one 
modality; other modalities are sigmoidoscopy, fecal occult blood testing (FOBT), and 
barium enema.  The following is a review of findings from colorectal cancer 
screening studies. 
  
1.  Perceived likelihood 
Perceived likelihood of getting colorectal cancer has been found to be 
correlated with screening behavior in multiple studies, to a limited extent.  In a 
study examining the association of perceived likelihood of colorectal cancer  
and colorectal cancer screening using FOBT, Vernon (1999) found a positive 
effect in two of eight studies and no effect in the remaining six.  All three studies 
of sigmoidoscopy showed a positive correlation between perceived likelihood 
and screening.41 None of the studies in Vernon’s review addressed screening 
colonoscopy.   
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More recently, studies found perceived likelihood to be correlated with past 
adherence to screening colonoscopy or sigmoidoscopy in three studies,42-44 but 
a fourth study showed no relationship between perceived likelihood and past 
use of sigmoidoscopy or FOBT.45  Looking at intention to get screening as an 
outcome, one study found no association between perceived likelihood and 
intention to receive screening in the future.45   
 
In contrast, a study of siblings of colorectal cancer patients found greater 
perceived likelihood of colorectal cancer to be associated with stronger 
intentions to receive colonoscopy in the future.46  These studies demonstrate a 
general trend of the significance of perceived likelihood in colorectal cancer 
screening behavior.  In addition, the perceived likelihood and intentions of 
siblings of colorectal cancer patients, a higher risk group who did demonstrate 
stronger intentions to get tested for colorectal cancer, may parallel the risk 
perceptions of colorectal cancer survivors. 
 
2.  Perceived benefits and barriers 
Perceived benefits and barriers have each been shown to be correlated with 
colorectal cancer screening, although results are somewhat mixed.  Three of 
four cross-sectional studies showed a correlation between higher perceived 
benefits and past use of colorectal cancer screening,36, 39, 47 while the fourth 
study showed no effect of benefits.38  One longitudinal study found no effect of 
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benefits on screening.35  Perceived barriers were associated with past 
screening in three studies,38, 39, 47 but had no influence in a fourth.36  One 
longitudinal study found that lower perceived barriers resulted in a higher 
likelihood of screening.35   
 
Both perceived benefits and perceived barriers show a trend of association with 
colorectal cancer screening.  However, because of the multiple possible 
modalities of colorectal cancer screening, cross-sectional study designs, varied 
instruments, and a variety of outcome measures, the effect of barriers and 
benefits on colorectal screening are not well understood. 
 
3.  Cues to action 
Cues to action have not been thoroughly studied in colonoscopy screening, but 
three studies found that the specific cue of physician recommendation of 
screening was associated with past colorectal screening use.45, 48, 49   
 
4.  Self-efficacy 
Self-efficacy, in the context of cancer screening, refers to an individual’s belief 
that he or she can achieve the goal of getting screened.  Two studies of self-
efficacy have shown that higher self efficacy is correlated with past colorectal 
cancer screening47 and intention to have colorectal cancer screening in the 
future.45 
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Taken together, previous studies of colorectal cancer screening suggest that, 
despite diverse outcomes and methodological issues, constructs in the HBM are 
associated with colorectal cancer screening.  The perceived barriers, perceived 
benefits, and other important cognitive factors identified in studies of screening 
colonoscopy can be used as a starting point for research on surveillance 
colonoscopy.     
Health beliefs have rarely been studied among survivors of colorectal cancer.  
The few studies that have addressed perceived likelihood for recurrence of 
colorectal cancer provide some evidence that survivors are concerned about 
recurrence of their cancer.  A multi-state survey study found that one year after 
diagnosis, 68% of colorectal cancer survivors fear that their illness will return.50  This 
is the top-ranked concern among a list of 29 items. Perceived likelihood was 
addressed more directly in a survey of 81 colorectal cancer survivors at an average 
of two years following treatment.  In this study, women survivors perceived a 28% 
chance of getting cancer again, and men perceived a 37% chance of getting cancer 
again.51  On a six-point scale of risk ranging from extremely low to extremely high 
chance of getting cancer again, both men and women perceived their risk as 
between “somewhat high” and “high”. Risk perception was found to decrease with 
time since diagnosis.  There was a relationship between risk perception and desire 
to change health behaviors, such as exercise, diet, weight loss, and smoking.51  
There was no effect of perceived likelihood on actual health behavior changes, 
although the cross-sectional nature of the study prevents drawing any conclusions 
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about whether earlier perceived likelihood influenced changes in health behaviors 
before the time period of the study.   
One study looked at variants of health beliefs among colorectal cancer 
survivors.  In a Canadian study of 96 colorectal cancer survivors who responded at a 
mean of 34 months after completing their treatment, participants were asked why 
their doctors were continuing to care for them after their surgery.52  Ninety-one 
percent responded that doctors were looking for recurrence, which indicates that 
they understood there was a risk for recurrence for survivors.  Ninety-two percent of 
respondents had a colonoscopy in the first five years after surgery, but no 
relationship between their perceived likelihood of getting colorectal cancer and 
having had a colonoscopy was evaluated.  This study also measured other health 
beliefs in relation to all types of follow-up for colorectal cancer, including 
gastroenterology visits, metastasis testing, chest radiograph, abdominal imaging, 
and colonoscopy.  The survey items, however, did not map well onto the constructs 
of perceived severity (“Follow-up of colon cancer is important to improve my chance 
of survival”), perceived benefits (“If the cancer returns there is no hope for further 
treatment”), and cues to action (“It is important for me to be involved in making 
decisions in my care”).  Survivors generally disagreed with statements describing 
barriers to care (means 1.5 – 2.2 on a scale ranging from 1 = strongly disagree to 4 
= strongly agree); barriers included follow-up taking too long, wait times being too 
long, and testing being too stressful.  Notably, these statements did not incorporate 
whether these problems with follow-up care influence attitudes toward getting care.52 
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No published studies have investigated whether the health beliefs of 
colorectal cancer survivors affect receipt of routine surveillance with colonoscopy.  
This is important because even if people with and without a history of colorectal 
cancer similar have attitudes toward colonoscopy itself (e.g., perceived discomfort, 
cost), colorectal cancer survivors may have different motivators for receiving 
colorectal exams than people without cancer. For example, colorectal cancer may 
be more salient to survivors of colorectal cancer.  Thus, they may weight the benefits 
and harms of colonoscopy differently than those who have never personally 
experienced colorectal cancer.  Applying the HBM to surveillance, rather than 
screening, is an important conceptual advance, because there is little data on 
whether the health beliefs contributing to colonoscopy use among the general 
population have the same effect on colonoscopy use among survivors of colorectal 
cancer. 
 
2.9  New approach to understanding nonadherence to colonoscopy guidelines 
 This dissertation seeks to advance our understanding of colonoscopy use 
among colorectal cancer survivors by addressing the gaps in our understanding of 
nonadherence.  First, this dissertation will update findings from earlier studies by 
using a recent, diverse, national data set to identify survivor characteristics that are 
associate with colonoscopy use.  The dissertation will focus not just on underuse, 
but also on the predictors of overuse.  These findings will be further enhanced by the 
inclusion of an assessment of primary care use.  Neither primary care use nor 
predictors of overuse have been assessed in prior studies.  Finally, this dissertation 
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will use the HBM to inform our understanding of survivor behavior and identify 
modifiable targets for intervention. 
 
2.10  Specific Aims 
This study will use data from the Cancer Care Outcomes Research and 
Surveillance (CanCORS) study.  Details about the study, including sample selection 
and measures, will be presented in detail in Chapter 3.  Briefly, CanCORS is a 
national multi-site population-based cohort study of cancer patients.  Medical record 
data and interview data were collected from about 4,000 colorectal cancer patients.  
This study uses data from the entire national sample as well as more detailed data 
from participants in the North Carolina site.  The national cohort uses data from the 
medical records and baseline interview data of all participants with colorectal cancer.  
The NC cohort used data from medical records and interviews from 4-year survivors 
of colorectal cancer that were enrolled at the North Carolina site.   Using CanCORS, 
this study has 3 specific aims.  Each aim corresponds to a paper in the dissertation. 
 
1.  Assess survivor characteristics contributing to variation in routine surveillance for 
colorectal cancer 14 months after surgery in the national cohort.     
  
2.  Assess factors contributing to the underuse and overuse of routine surveillance 
for colorectal cancer 4 years after diagnosis in the NC cohort. 
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3.  Understand the relationship between health beliefs regarding colorectal cancer 
surveillance and intentions to engage in routine colorectal cancer screening in the 
future in the NC cohort. 
 
2.11  Hypotheses 
 The following hypotheses address colonoscopy utilization and its predictors, 
as shown in the conceptual model above.   
 
Aim 1.  Assess survivor characteristics contributing to variation in routine 
surveillance for colorectal cancer 14 months after surgery in the national cohort.    
 
H1.  Survivors who have non-white race, older age, no spouse or partner, less 
education, lower income, no insurance, and more severe comorbidities are 
less likely than their counterparts to receive an initial colonoscopy within 
fourteen months. 
 
This hypothesis addresses the sociodemographic factors that may affect 
access to high quality health care as well as attitudes toward the medical 
system, and it reflects the disparities seen in other studies of colonoscopy 
use.  The clinical factor of demographics may be related to colonoscopy use, 
in that those who are too frail may not be offered colonoscopy, or they may 
be less willing to undergo the procedure if their health is otherwise poor. 
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Aim 2.  Assess factors contributing to the underuse and overuse of routine 
surveillance for colorectal cancer 4 years after diagnosis in the NC cohort. 
 
H2.1.  Survivors who have non-white race, older age, no spouse or partner, 
less education, lower income, no insurance, and more severe comorbidities 
are less likely than their counterparts to receive an initial routine 
colonoscopy within four years. 
 
Similar to H1 above, these sociodemographic factors may affect access to 
care and attitudes toward the medical system, and an association with 
comorbidities may reflect whether survivors are too frail to be offered or to 
undergo colonoscopy. 
 
H2.2.  Survivors who did not have colorectal cancer screening before 
diagnosis will be less likely than those who did have screening to receive an 
initial routine colonoscopy within four years. 
 
Survivors who had colorectal cancer screening, no matter the modality, may 
be the same people who have both the access to ongoing care and an 
interest in testing as a preventive measure.   
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H2.3.  Survivors who have not seen their primary care physician since 
completing treatment are less likely than those who did see a primary care 
physician to receive an initial colonoscopy within four years. 
 
If primary care physicians refer survivors for colonoscopy, those who have 
seen a primary care physician may be more likely to be referred.  Also, 
survivors who see primary care physicians may have better access to high 
quality ongoing care, and they may see other physicians who refer them for 
colonoscopy. 
 
H2.4.  Survivors who have younger age, higher income, insurance, and fewer 
comorbidities are more likely than their counterparts to have received a 
second (or more) colonoscopy within four years. 
 
This hypothesis and hypothesis 2.5 (below) suggest that the factors that 
make people less likely to get a first colonoscopy also make them less likely 
to have further colonoscopies.  It is possible that among those who get any 
colonoscopies, some physicians and survivors get more than necessary just 
to be sure that recurrences and second primaries have not appeared. 
 
H2.5. Survivors who have seen a primary care physician in the past three 
years are more likely than their counterparts to have received a second (or 
more) colonoscopy within four years. 
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Although primary care physicians may steer survivors toward appropriate 
use of care, this hypothesis proposes that those survivors who get more 
care are also more likely to get too many colonoscopies. 
  
Aim 3.  Understand the relationship between health beliefs regarding colorectal 
cancer surveillance and their intentions to engage in routine colorectal cancer 
screening in the future in the NC cohort. 
 
H3.1.  Health beliefs are associated with intention to receive colonoscopy in 
the next five years. 
 
Health beliefs, as a group of constructs, will be associated with colonoscopy 
intentions.  This is a test of the predictive validity of HBM in the context of 
surveillance colonoscopy. 
 
H3.2.  Survivors’  perception of greater likelihood of getting colorectal cancer 
again is positively correlated with a greater intention to receive routine 
colonoscopy in the future. 
 
Among the health beliefs, perceived likelihood of getting colorectal cancer 
again will be predictive of intentions.  Perceived likelihood has been shown 
to relate to screening behavior.  In survivors, perhaps the experience of 
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colorectal cancer increases the salience of colorectal cancer and, therefore, 
the survivors’ perceived likelihood of getting it again becomes a more 
important motivator of behavior. 
 
H3.3.  Survivors who had routine colonoscopy during the past three years are 
more likely than those who did not to intend to receive routine endoscopy in 
the future.   
 
Having had a colonoscopy may be a strong predictor of whether survivors 
will have colonoscopy again, because these survivors have already 
performed this behavior once.  Even if the test is unpleasant, these survivors 
at least have the access to colonoscopy and have been motivated to have 
colonoscopy before. 
 
H3.4.  Survivors who have white race, younger age, a spouse or partner, more 
education, higher income, insurance, and fewer comorbidities are more likely 
than their counterparts to intend to receive routine colonoscopy in the future. 
 
As in hypotheses H1 and H2.1, these sociodemographic variables may 
relate to access to screening and attitudes toward medical care.  Survivors 
with more severe comorbidities may be too frail to be referred to undergo 
colonoscopy, or they may feel to ill to undergo colonoscopy even if referred. 
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2.12  Implications  
This dissertation examines factors that influence colonoscopy use by 
survivors of colorectal cancer.  We extend previous studies by using a recent, large, 
national, diverse data source (for Aim 1), including primary care use as a predictor 
(all Aims), focusing on overuse in addition to underuse (Aim 2), and examining 
health beliefs of survivors, which can be used to design effective interventions to 
increase guideline-concordant colorectal cancer (Aim 3). 
This study updates estimates of underuse and overuse of surveillance 
colonoscopy, and it identifies vulnerable populations for both types of nonadherence. 
Separating those who underuse colonoscopy from those who overuse can allow 
health organizations and providers better target which survivors need particular 
attention in ensuring that they receive appropriate ongoing surveillance. 
The role of ongoing care, and specifically primary care, for survivors has 
become of utmost importance as researchers and clinicians attempt to improve 
continuity of care for survivors.  Including primary care use as a predictor of both 
colonoscopy use and intentions provides more information about whether primary 
care use correlates with adherence to guidelines.  Although this study cannot 
determine causality, if primary care is a significant predictor, it may be worth further 
exploration to understand whether primary care physicians are responsible for 
colonoscopy use or are an indicator of access to ongoing preventive care. 
Finally, understanding health beliefs can guide the development of 
interventions and strategies that are directed at survivors themselves.  Health beliefs 
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that are found to be associated with intentions to undergo colonoscopy can be 
targeted in survivor-provider communications and interventions directed at survivors.  
Adherence to colonoscopy guidelines maximizes the benefit gained from 
ongoing prevention for colorectal cancer survivors and can reduce mortality from 
second colorectal cancers and recurrences.   This study is an important step 
towards understanding the problem, with the goal of improving adherence and 
outcomes for colorectal cancer survivors.   
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III.  METHODS 
 
3.1  CanCORS study and populations 
To investigate predictors of colonoscopy use, this study used data from 
the CanCORS study.  The CanCORS study is an ongoing cohort study designed 
to understand how the processes of cancer care can influence outcomes.  The 
original cohort included patients diagnosed with colorectal or lung cancer 
between May 2003 and October 2005 in multiple regions of the U.S.  The study 
centers included 4 geographically defined sites, 10 Veterans Administration (VA) 
hospitals, and 5 managed care organizations.  The geographically defined 
regions were Los Angeles county, Northern California (9 counties), Iowa, 
Alabama, and North Carolina (33 counties).  The 10 VA hospitals were located 
around the country: Baltimore, MD; Biloxi, MS; Chicago, IL; Durham, NC; 
Minneapolis, MN; Nashville, TN; New York, NY; Portland, OR; Temple, TX; and 
Tucson, AZ.  The 5 managed care organizations were part of the National 
Cancer Institute (NCI) funded Cancer Research Network (CRN): Seattle, WA; 
Boston, MA; Detroit, MI; Hawaii; and Portland, OR.  The Iowa site only included 
lung cancer patients, and the North Carolina site only included colorectal cancer 
patients. 
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Patients agreeing to participate were interviewed by telephone within 3 
months of their diagnosis and again 1 year after diagnosis.  The interviews 
captured data on clinical parameters, current disease status, demographic 
characteristics, treatment strategies, participation in clinical trials, assessment of 
cancer care, quality of life and symptoms, goal of treatment, health history, health 
behaviors, insurance, hospital admissions, and utilization.  If participants died 
after enrollment, efforts were made to interview proxies or surrogates.   
Participants in the North Carolina CanCORS site only were interviewed 
again 4 years after diagnosis.  To address the aims of this study of colorectal 
cancer surveillance, items were added to the 4-year interview to assess:  past 
utilization of surveillance, cognitive factors that may influence surveillance, and 
likelihood of future surveillance (see Section C.4 for a description of these items).  
Data collection for the baseline and one-year interviews is complete.  Data 
collection for the four-year interviews is ongoing and will be completed in 
September 2008. 
Participants who consented to having their medical records abstracted 
had medical record data from 3 months prior to diagnosis through 15 months 
after diagnosis.  Data included clinical parameters, current disease status, 
demographics, diagnostic and treatment strategies, participation in clinical trials, 
health history, health care visits, and hospital admissions during the 15-month 
period.  Data abstraction was performed by nurses at the Carolinas Center for 
Medical Excellence who received formal training.  Medical record abstraction was 
completed in 2007. 
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3.2  Definition of Cohorts for Specific Aims 
 For Aim 1, 3876 participants with colorectal cancer who had complete 
medical records from all of the CanCORS sites formed the national cohort.  For 
Aims 2 and 3, the NC cohort comprised participants from 33 counties in North 
Carolina who were identified through the North Carolina Central Cancer Registry 
and who completed the baseline, 1-year, and 3-year interviews.  The protocols 
for Aims 2 and 3 are shown in Figure 3.1.  The specific sample size for the final 
analytic samples are not shown here; individual papers describe eligibility criteria 
that further reduce these sample sizes. 
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Figure 3.1.  Protocol to enroll patients for North Carolina cohort (Aims 2 
and 3). 
 
Inception NC Cohort 
1917 patients with newly diagnosed 
CRC in NC 
Baseline interview (N=1010) 
768 survivors 
128 surrogates for living survivors 
85 surrogates for deceased 
patients 
29 self-administered 
1-year interview (N=736) 
680 survivors 
56 proxies for deceased 
participants 
531 refused, unreachable, 
incapable 
5 not sampled 
363 ineligible 
8 no consent to 
interviews 
4-year cohort (Aims 2 and 3) 
234 eligible survivors 
85 deceased at baseline  
29 self-administered at 
baseline 
160 refused, unreachable, 
incapable 
15  deceased (no 
316 not yet at 3.5 years 
from diagnosis 
74 refused, unreachable, 
incapable 
18 deceased  
13 in treatment 
14 had colectomy 
23 had metastasis or new 
primary 
 
4-year interview (N=278) 
278 survivors 
 
13 no surgery date 
16 no stage 
8 stage IV 
7 stage 0 
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 At the time of the study, the sample size for each cohort was not known.  The 
a priori power of each analysis was based on estimated sample sizes.   
Approximately 4,000 participants in the inception cohort had colorectal cancer. 
Based on national data from the Surveillance, Epidemiology, and End Results 
(SEER) Program from  1973-2003,1  the one-year survival rate is 83.7%.  Thus, I 
estimated that 3,349 of the 4,000 patients would be alive at one year.  Allowing for 
further deaths within the study period (~100), incomplete charts (~40), and refusals 
(~40), I estimated that the national cohort would include approximately 3169 people.  
I did not estimate further attrition due to censoring or other eligibility criteria (e.g., 
survivors had to have had curative surgery).  
For the NC cohort, an estimated 1000 CanCORS participants came from the 
North Carolina site.  SEER data estimates a 4-year survival rate of 67.8%.  Thus, we 
estimated that 678 participants would be alive at four years.  After excluding patients 
lost to follow-up or refused to participate (~80), not completed active treatment for 
their original cancer (~10), and having either a second primary cancer (~10) of a 
local recurrence (~80), I estimated that 498 survivors would form the NC cohort. 
 For Aim 1, an analysis with at least 800 participants will yield a power of 80% 
for regressions with R2 values greater than 0.01; therefore, analyses of an estimated 
3,169 participants would have sufficient power for a regression with an R2 of 0.01 or 
less.  With an estimated 500 participants for Aims 2 and 3, and using two-tailed 
hypotheses, regression analyses with R2 values greater than or equal to 0.01 will 
yield a desired power of 80% to reject the null hypothesis.2 To account for a variety 
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of sample sizes, Table 3.1 shows minimum R2 values that will yield 80% power for 
various sample sizes. 
 
Table 3.1.  Minimum R2 values yielding 80% power. 
Sample size R2 
100 0.07 
300 0.02 
500 0.01 
800 and up 0.01 
 
3.3  Measures 
There are 3 sets of dependent variables in this study.  All measures can be 
found in the questionnaire in Appendix A. 
 
Aim 1.  Receipt of colonoscopy in first 14 months after surgery.   
This dichotomous variable was abstracted from the medical records of all 
patients in the national cohort.   The 14-month period was chosen because three 
mainstream guidelines recommend a colonoscopy at 1 year, 3-5 and a colonoscopy 
at one year would be appropriate according to four more guidelines that were in 
place during the study period.6-9   In addition, the 14-month period was chosen to 
balance the time allowed for survivors to have surgery with adequate post-surgical 
follow-up analysis time within the 15 months of post-diagnosis data. 
 
Aim 2.  Receipt of colonoscopy in four years.   
This dichotomous variable is measured by self-report in the 4-year telephone 
survey in the NC cohort.  The question and the description of colonoscopy were 
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Vernon et al.’s suggested measures to assess colonoscopy use, which have been 
recently validated among asymptomic adults eligible for screening.10, 11  If survivors 
reported having had a colonoscopy, they were asked how many.  To establish 
whether each test was routine or prompted by symptoms, they were asked the 
reason for getting a colonoscopy, a question which also came from Vernon et al.’s 
suggested measures.10  The reasons include: part of a routine exam or checkup, 
because of a symptom, follow-up of an earlier abnormal test, other, and not sure. 
 The appropriate timing of colonoscopy depends on the guidelines in place 
when a participant was diagnosed and followed.  Between 2003 and 2006, 
guidelines varied in the recommended intervals between colonoscopies:  the timing 
of the first recommended colonoscopy ranged from 1 to 3 years after diagnosis or 
surgery,3-7, 9, 12-15  and the timing of subsequent routine surveillance colonoscopies 
ranged from 3 to 5 years after the first colonoscopy. 3-7, 9, 12-15  Further, the 
recommended timing of colonoscopies depended on whether patients received a 
colonoscopy before having surgery.  Current guidelines, as of 2006, recommend a 
preoperative colonoscopy when possible, followed by a colonoscopy one year after 
surgery.  In some cases, however, obstruction of the colon precludes a preoperative 
colonoscopy, and guidelines recommend a first colonoscopy six months after 
surgery. Because the abstracted medical records only extended 3 months before 
diagnosis (and therefore not the full 6 months before surgery for many participants), 
the presence of a preoperative colonoscopy was unknown. 
 For this study, we conservatively interpreted these guidelines such that at 4 
years after diagnosis, having had no colonoscopies would be considered underuse 
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according to any guideline.  Having had 1 colonoscopy would be appropriate under 
any guideline.  Having had 2 colonoscopies was considered appropriate if the 
second colonoscopy occurred after 3 years, but it was considered overuse if it 
occurred before 3 years after surgery.  Finally, having had 3 or more colonoscopies 
was considered overuse under any guideline.  This classification accounted for 
variations in recommended surveillance intervals. 
 
Aim 3.  Intention to receive colonoscopy or sigmoidoscopy in the next five years.   
In the proposed study, intention was assessed by self-report in the four-year 
telephone interview.  A five year interval (i.e., intention to have colonoscopy in the 
next 5 years) was used, because regardless of guidelines and regardless of 
previous surveillance, every survivor would be due for at least one colonoscopy 
within five years at the time of interview.  Three items were used to measure 
intention to get colonoscopy, because each measured slightly different aspects of 
intention.  This was in part a safeguard to maximize the probability that there would 
be variation in the dependent variable.  The first question was a planning question, 
which measured whether the survivor planned to have a colonoscopy and, if so, 
when.  The second question measured the survivors’ expectation of having a 
colonoscopy, and the third question measured desire to have a colonoscopy.  The 
planning measure was dichotomous, and the desire and expectation measures were 
coded on five-point Likert scales.   
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The independent variables in this study include clinical variables, 
sociodemographic variables, measures of health care use, and measures of health 
beliefs. 
 
Clinical characteristics 
Abstracted medical records contained information on the extent of disease 
spread and lymph node involvement, site of disease (colon or rectum), and 
comorbidities.  Staging was determined using collaborative staging, or if it was 
unavailable, from the best available data from the registry, medical records, or 
interviews.   Comorbidity was assigned as none, mild, moderate, or severe using the 
Adult Comorbidity Evaluation (ACE-27) index.16-18  Both staging and comorbidity 
were determined by the central CanCORS statistical group.  
 
Sociodemographic characteristics 
The baseline interview included measures of demographics (i.e., age, gender, 
ethnicity, marital status, income) and insurance status.  When unavailable in the 
interviews, age, gender, and ethnicity were determined from the medical record.  
Age was a continuous variable, gender was dichotomous, and the rest were 
categorical variables that were coded as a series of dichotomous variables. 
 
Health care use.  
Four measures related to health care utilization.  First,  to assess whether the 
patient had seen a primary care physician (PCP), the baseline questionnaire 
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contained an item assessing whether the patient had seen their PCP since 
completing treatment for colorectal cancer and, if so, the PCP’s specialty.  Second, 
past use of colorectal cancer screening was assessed using suggested measures 
from Vernon et al.10 The final two measures, visits to a medical oncologist and 
adjuvant chemotherapy, were abstracted from the medical record.  The coding for all 
utilization measures was dichotomous (yes/no). 
 
Perceived likelihood of second colorectal cancer   
We asked survivors their perceived likelihood of “getting cancer in your colon 
or rectum again.”   This description was intentionally phrased to capture either a 
local recurrence or a new primary colorectal cancer for two reasons.  First, although 
colonoscopy rarely detects recurrences in the colon that are at a treatable stage, this 
occurs with rectal cancer more frequently, and is therefore appropriate to include.  
Second, even if colonoscopy doesn’t extend survival, local recurrences will still be 
detected. 
Because a person’s perceived likelihood of getting cancer again in their 
lifetime may depend on whether they receive routine colonoscopies at regular 
intervals, the assessment of perceived likelihood measured the participant’s 
perception of likelihood was conditioned on not having regular colonoscopies.19 
Response options were coded as a five-point Likert scale.   
 
Perceived benefits.   
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A validated set of benefits and barriers20 has been used in other studies to 
predict colorectal screening behavior.21, 22  Respondents were asked to reply to each 
item using a five-point scale ranging from strongly agree to strongly disagree.20  
Slight modifications made from the original wording to account for differences 
between screening colonoscopy and surveillance colonoscopy.  Changes from the 
original are listed in Appendix B.   Cronbach’s alpha was examined to confirm that 
the scale had acceptable internal reliability.  The item-deleted alphas were examined 
to confirm that all of the items should be included.  The items were included as a 
scale if they had acceptable internal consistency.  If they had internal consistency, 
the benefit items were summed to create a scale as a continuous variable.   
 
 Barriers.   
 The list of adapted validated barriers also came from Rawl et al.20  Like the 
benefits above, some changes were made from the original wording.  Changes from 
the original are listed in Appendix B.  The items were included as a scale if they had 
acceptable internal consistency. 
 
Cues to action.   
 These items assess whether survivors were referred for routine colonoscopy.  
An additional question measured whether any of those doctors was their primary 
care provider.   
 
3.4  Missing data 
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 For each study, observations which were missing values for the dependent 
variable were excluded from the analyses.  When values for independent variables 
were missing, multiple imputation techniques were used to impute these values.  
The multiple imputation procedure in Stata (ice) used available information from 
nonmissing values of the same variable and values from other related variables.23-25  
For the studies in this dissertation, all variables included in each model were 
included in the imputation procedure.  Multivariable regression techniques predicted 
the missing values.  In addition, the procedure incorporated random values from the 
residuals arising from the regression analyses, in order to account for the uncertainty 
of missingness.26  In each study, the procedure was repeated five times to produce 
multiple data sets, so that variability across data sets could be used to adjust 
standard errors, which would otherwise be too low.  The number of repetitions (5) 
was chosen to match the number of repetitions used by the CanCORS statistical 
core.  As a sensitivity analysis, for each study, the results were compared to those 
arising from 10 repetitions, and the direction and significance of each predictor did 
not change.  This multiple imputation procedure assumed the data were missing at 
random, such that whether the value is missing is unrelated to the value of the 
variable that is missing.26  It is not possible to test this assumption. 
 
3.5  Overview of analyses 
 For each Aim, descriptive statistics described the characteristics of the 
sample.  Bivariate analyses demonstrated the association between each 
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independent variable and the outcome.  A multivariate analysis was performed for 
each aim.  The specific analytic techniques varied with the nature of the dependent 
variables, and they are presented within each individual paper.   
In addition, for Aim 1, sensitivity analyses addressed the effect of censoring 
by looking at both shorter and longer analysis windows.  Marginal effects of each 
dichotomous predictor were calculated by comparing the predicted values of 
colonoscopy use when the predictor had one value for all observations to the 
predicted values of colonoscopy use when the predictor had the other value for all 
observations.  Similarly, for Aim 2, sensitivity analyses were used to determine 
whether missing data on dates for colonoscopy affected the results. 
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IV.  VARIATION IN THE USE OF SURVEILLANCE COLONOSCOPY AMONG 
SURVIVORS OF COLORECTAL CANCER 
 
4.1  Abstract 
 
Background:  Clinical practice guidelines recommend routine colonoscopies at 
regular intervals for survivors of colorectal cancer (CRC).  We describe 
colonoscopy rates and their geographic, sociodemographic, clinical, and health 
services correlates.  
 
Methods:  We studied CRC survivors enrolled in the Cancer Care Outcomes 
Research and Surveillance (CanCORS) study.  Eligible survivors had curative 
surgery for CRC and were alive without recurrences 14 months after surgery with 
curative intent.  Data were from patient interviews and medical record 
abstraction. We used a multivariate logit model to identify predictors of 
colonoscopy use. 
 
Results: 40% of the 1893 survivors received a colonoscopy within 14 months 
after surgery.  Use varied by region, with an almost three-fold difference (20% to 
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58%) in colonoscopy rates across study centers.  Significant predictors of 
colonoscopy underuse were having rectal cancer (odds ratio [OR] = 0.66, 95% 
confidence interval [CI]: 0.50-0.87) and having more severe comorbidities (OR = 
0.52, 95% CI: 0.36-0.75).  Survivors with a visit to a primary care physician 
(OR=1.27, 95% CI: 1.04-1.57) or medical oncologist (OR=1.52, 95% CI: 1.06-
2.18) were more likely to have had colonoscopy.   
 
Conclusions:  The majority of survivors did not receive follow-up colonoscopy 
within 14 months.  Some geographic variation may be explained by regional 
differences in medical record abstraction methods, but the effect was large 
enough to suggest that surveillance practices vary by region.  The association of 
primary care and medical oncology visits with colonoscopy use suggests that 
access to routine office visits following surgery affects routine surveillance.   
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4.2  Introduction 
 
Colorectal cancer (CRC) survivors need ongoing preventive care even 
after their cancer treatment is complete.  Because CRC survivors are at risk for 
both local recurrences and second primary cancers1, clinical practice guidelines 
from multiple gastroenterological and oncological societies have long agreed that 
survivors who are treated for cure should receive ongoing routine surveillance 
with colonoscopy.2-11  These recommendations are intended to reduce mortality 
by detecting second colorectal cancers and some local recurrences early enough 
to treat.  Failing to perform routine colonoscopies may result in tumors not being 
detected until after patients become symptomatic, thus reducing treatment 
options and potentially increasing mortality.    
The recommended interval between colonoscopies, however, has varied.  
Most recently, the clinical practice guidelines developed by the American Cancer 
Society and the U.S. Multi-Society Task Force on Colorectal Cancer recommend 
ongoing colorectal surveillance for people with CRC via colonoscopy at 1 year 
after surgery, and then at 3 years and, if normal, every 5 years thereafter.11  
Before 2006, there were multiple conflicting guidelines about the timing of 
colonoscopies for CRC survivors, recommending the first surveillance 
colonoscopy at 1 year or 3 years after diagnosis or surgery. 2-10  (Appendix C) 
Accordingly, the timing of actual colonoscopy utilization has varied as well. 
Many survivors do not receive their first surveillance colonoscopy within 1 year 
after surgery, and some never undergo surveillance.  Estimates of receipt of 
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CRC survivors’ colon exams (including colonoscopies) range from 52-61% within 
18 months of diagnosis 12-16, 60% to 76% within 3 years12, 16, 17, and only 65-80% 
within 5 years.12, 14, 17   
Of more concern, however, are differences in routine surveillance by 
survivor characteristics.  Studies have shown that such factors as race and 
ethnicity, age, marital status, income, geographic region, site of the tumor, 
comorbidities, and stage may be associated with whether survivors undergo 
appropriate surveillance.12-19   
Prior studies, however, have three important limitations.  First, they are 
older studies, using data from 1986 through 2002.12-19  Treatment options and 
health care systems have evolved over the past 20 years.  Because these 
studies reflect data gathered when earlier guidelines were in effect, they include 
other colon exams (in addition to colonoscopy) in their analysis.  As of 2003, the 
U.S. Multisociety Task Force on Colorectal Cancer recommended colonoscopy 
specifically (although sigmoidoscopy is recommended in addition for rectal 
cancer survivors)5, 11, and it is unclear whether older findings for colon exams 
other than colonoscopy apply to colonoscopies alone.  Second, these studies of 
colon exams have been restricted to specific age and insurance groups (e.g., 
receiving Medicare), clinic-based populations, or regional health systems.12-17, 19   
Third, many previous studies have been limited to administrative data12, 13, 16-19, 
which may not capture adequate detail about survivors’ clinical characteristics.   
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We used interview and medical record data from a recent nationwide population-
based sample of CRC survivors to study the proportion of CRC survivors who 
undergo routine colonoscopies, and whether colonoscopy use varies according 
to region and characteristics of survivors.  Specifically, we sought to:  (1) 
estimate the rate of use of surveillance colonoscopy among CRC survivors 14 
months after having surgery and (2) identify characteristics of survivors who 
received colonoscopy in that time period.   
 
4.3  Methods 
 
The Cancer Care Outcomes Research and Surveillance (CanCORS) 
Consortium.   
The study used data from the CanCORS Consortium, a multi-regional 
U.S. population-based cohort study of lung and CRC cancer. A detailed 
description of CanCORS has been published elsewhere.20, 21  Briefly, patients 
diagnosed with CRC or lung cancer were identified an average of 1.8 months 
after diagnosis (standard deviation [s.d.] = 1.4 months).  For CRC, the regions 
include 4 geographic sites (Northern California, Los Angeles, Alabama, and 
North Carolina); 14 Veterans Affairs (VA) Medical Centers; and 6 members of the 
Cancer Research Network, a network of managed care organizations designated 
by the National Cancer Institute to conduct research on cancer prevention and 
control.22  The VA sites were considered a single VA study center, and the 6 
managed care organizations were considered a single managed care study 
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center.  CRC patients in CanCORS were diagnosed from May 2003 through 
October 2005.   
 
Data sources.  
Data for this study came from two sources.  First, for eligible participants 
providing informed consent, medical record audits were conducted by abstractors 
trained by a central CanCORS team.  Data on cancer-related medical visits and 
procedures were extracted for the period beginning 3 months before diagnosis 
through 15 months after diagnosis.  Second, interviews with participants or their 
proxies (in the case of survivor illness) were conducted approximately 4 months 
after diagnosis.  Interviews elicited information about symptoms, satisfaction with 
care, and other topics for which survivors are an important source of information.  
A centralized statistical and computing core derived key variables, including 
staging, comorbidity, and adjuvant treatment variables, from both abstracted 
medical records and participant interviews.     
 
Inclusion and exclusion criteria 
We restricted analyses to survivors who: (1) had stage I, II, or III colorectal 
cancer; (2) received surgery within one month of diagnosis (so that they had at 
least 14 months of follow-up time), (3) were alive at 14 months after surgery (so 
that they had the opportunity to receive colonoscopy); and (4) had complete 
medical record data.  Participants who had local recurrences within the study 
period were excluded, unless the recurrence was preceded (and therefore 
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possibly diagnosed) by a colonoscopy.  Participants who had colonoscopies 
performed within 60 days after surgery were excluded under the assumption that 
the colonoscopy was associated with surgical compilations, was prompted by 
symptoms, or was conducted in place of a preoperative colonoscopy.  
 
Colonoscopy use.   
During the CanCORS study period, conflicting guidelines for colonoscopy 
surveillance were in effect, with the first routine surveillance recommended at 1 
or 3 years after surgery or diagnosis.  Our primary outcome was receipt of the 
first surveillance colonoscopy, defined as having this procedure within 14 months 
of surgery.  The 14-month period was chosen because 3 mainstream guidelines 
recommend a colonoscopy at 1 year, 4, 10, 11 and a colonoscopy at 1 year would 
be appropriate according to 4 more guidelines that were in place during the study 
period.3, 6, 7, 23   In addition, the 14-month period was chosen to balance the time 
allowed for survivors to have surgery with adequate post-surgical follow-up 
analysis time within the 15 months of post-diagnosis data.   
 
Covariates.   
Sociodemographic data included age (from the medical record) and sex, 
race and ethnicity, income, insurance, marital status, and education (from the 
interviews).  Clinical characteristics came predominantly from the medical 
records, and they included site of the tumor, stage at diagnosis, and presence 
and severity of comorbidities.  Staging was determined using collaborative 
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staging, or if it was unavailable, from the best available data from the registry, 
medical records, or interviews.   Comorbidity was assigned as none, mild, 
moderate, or severe using the Adult Comorbidity Evaluation (ACE-27) index.24-26   
Adjuvant treatment was defined as having had chemotherapy or radiation 
therapy within 6 months after surgery.  Finally, visits to primary care providers, 
visits to medical oncologists, and chemotherapy use came from the medical 
records. 
 
Data analyses.  
Missing data were imputed using an iterative multivariate regression 
technique in Stata.27  Imputed data were used for all analyses.  Dichotomous 
predictor variables that had less than 5% of the sample in one category were 
excluded from all analyses.  We used logistic regression to examine bivariate 
and multivariate relationships between survivor characteristics (clinical and 
demographic) and receipt of colonoscopy.  We calculated odds ratios for the 
effect of each predictor on colonoscopy use and conducted Wald χ2 tests of joint 
significance for categorical variables.28   
To describe the magnitude of the effect of the dichotomous predictors on 
the likelihood of colonoscopy use, we computed average changes in predicted 
probability with a multi-step process.    For each variable of interest, we 
subtracted the expected value of the dependent value when the variable was 
equal to 0 from the expected value of the dependent value when the variable was 
equal to 1.  The difference is the average change in predicted probability 
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resulting from having the population change from the first (reference) value of the 
predictor to the second (nonreference) value.  See Madden et al. for an example 
of this methodology.29 
 
4.4  Results 
 
After excluding ineligible participants, 1,893 survivors were included in the main 
analysis (Figure 4.1).  The largest number of excluded participants were the 528 
participants who had surgery more than 1 month after diagnosis and therefore 
were not followed long enough for this analysis.  Most survivors (82%) had a 
primary colon, as opposed to rectal, cancer.  Demographic and clinical 
characteristics of the cohort are provided in Table 4.1.   Because of small cell 
sizes, the race / ethnicity variable was collapsed into four categories (White, 
Black, Hispanic, and other).  The other category comprised 10% of the sample, 
and it included 46% Asian, 28% more than one race, 18% unknown, 5% 
American Indian, 2% Native Hawaiian, and 1% other Pacific Islander participants.  
Insurance status (i.e., whether the participant had insurance), whether the 
participant had adjuvant radiation, and whether the participant spoke English 
were excluded from the subsequent logistic regression analyses because of 
minimal variation in these variables.  
Across all sites, only 40% (N=751) of the sample had a colonoscopy within 
14 months after surgery.  In bivariate analyses, colonoscopy use varied by site of 
the tumor, comorbidities, marital status, study center, seeing a primary care 
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provider, seeing a medical oncologist, and having adjuvant chemotherapy.  
(Table 4.2)  
In multivariate analysis, the only demographic variable that influenced 
receipt of colonoscopy was race – survivors who were neither of white, black, nor 
Hispanic race (“other” race)  were significantly more likely to undergo 
colonoscopy within 14 months than white survivors (odds ration [OR] = 1.52, 95% 
confidence interval [CI]: 1.08 – 2.13).  (Table 4.2)  A post-hoc χ2 test showed that 
other race survivors were also more likely to get timely colonoscopy than black 
survivors (χ2[2] = 11.02, p < 0.05).  Colon cancer survivors were more likely than 
rectal cancer survivors to have received colonoscopy (OR = 1.52, 95% CI: 1.16 – 
1.99). Survivors with severe comorbidities were less likely to have received a 
colonoscopy than those with no comorbidities (OR = 0.51, 0.35 – 0.74).    Post 
hoc χ2 tests showed that survivors with severe comorbidities were also less likely 
to have received a colonoscopy than survivors with moderate or mild 
comorbidities (χ2 = 4.68 and χ2 = 14.09, p-values <0.05, respectively).  Survivors 
diagnosed at stage III were less likely to have a colonoscopy than those 
diagnosed at stage I (OR = 0.69, 95% CI: 0.50 – 0.96).  Having seen a primary 
care provider in the first year after diagnosis (OR = 1.27, 95% CI 1.03 – 1.57), 
having seen a medical oncologist (OR = 1.49, 95% CI: 1.04 – 2.13), and having 
had adjuvant chemotherapy (OR = 1.69, 95% CI: 1.28 – 2.23) were all positively 
associated with colonoscopy.   
 Study centers were strongly associated with colonoscopy use.  Compared 
to survivors at managed care organizations, survivors at the Northern California 
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site were the least likely to receive colonoscopy (OR = 0.46, 95% CI: 0.32 – 
0.66), and survivors in North Carolina were the most likely to receive 
colonoscopy (OR = 2.44, 95% CI: 1.77 – 3.36). 
 The magnitude of the statistically significant effects was calculated as an 
average marginal effect, indicating the change in probability of receiving a 
colonoscopy if every study participant first had the reference value of an 
independent variable and then changed to the indicator value.  If every 
participant in the study changed from not seeing a primary care provider to 
seeing a primary care provider, the likelihood of receiving a colonoscopy would 
increase by 5 percentage points on average.  Similarly, a change from not having 
adjuvant chemotherapy to having adjuvant chemotherapy would increase the 
likelihood of receiving a colonoscopy by 11 percentage points, on average.  
(Appendix D) 
 
4.5  Discussion 
 
Because CRC survivors are at increased risk for a subsequent primary or 
recurrent CRC compared with the general population, guidelines suggest regular 
surveillance via colonoscopy.2-7, 10, 11, 23, 30  Previous studies found that the rate of 
surveillance colonoscopy among CRC survivors is low; however, these studies 
used older data sets which limit generalizability.12-15, 17, 19, 31  Using rich medical 
record and interview data from a recent multi-regional population-based cohort of 
CRC survivors, we extended prior research on surveillance colonoscopy among 
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CRC survivors. This registry-based study using medical record abstraction 
included survivors with a range of insurance types, ages, and ethnic 
backgrounds, providing the study with strong external validity. 
We found that the proportion of CRC survivors receiving surveillance 
colonoscopy within 14 months of surgery is low (40%) across all regions and 
groups.  We conducted sensitivity analyses comparing different lengths of post-
surgical follow-up duration within the limits of our data (13 months, 13.5 months, 
14.5 months, and an analysis including all lengths of follow-up, including 
survivors who had data beyond 15 months after diagnosis).  The four sensitivity 
analyses (results not shown) confirmed that the study findings are robust, 
regardless of the length of follow-up used in calculating adherence to guidelines, 
although analyses with a longer follow-up than 15 months was not possible.  
(Appendix E) 
The rate of colonoscopy use reported in previous studies has not been 
this low; studies of colonoscopy use at 18 months after diagnosis have found 
higher rates of surveillance (52-61%).12-15  One possibility for this discrepancy is 
the diverse population-based CanCORS cohort that more accurately represents 
a national population of CRC survivors.  The higher estimates from prior studies 
simply may be due to the additional analysis time, or the inclusion of other colon 
exams (such as sigmoidoscopy and barium enema) in addition to colonoscopy.12-
15  However, two of the studies that included sigmoidoscopy and barium enema 
reported that colonoscopies comprised 70-97%12-14 of all colon exams, 
suggesting that other colon exams cannot fully account for the higher utilization 
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rate in these earlier studies.  The lower rate in this study may be a reflection of 
more recent data, with colonoscopy utilization having changed since earlier 
studies.  Cooper and Payes investigated colonoscopy use between 1999 and 
2004 and found that the number of colonoscopies performed within the first year 
after diagnosis decreased over time. 16   The authors suggested that survivors 
may be delaying their first colonoscopy until after 1 year.  It is possible that since 
2002, the average time of receipt of the first postoperative colonoscopy has 
become further delayed beyond 14 months.    
 Clinical factors were strongly associated with colonoscopy use.  Rectal 
cancer survivors were less likely to get colonoscopy than colon cancer survivors.  
Our findings mirror those of earlier studies in which colon cancer survivors were 
more likely to have colonoscopies than rectal cancer survivors14, 16-18, although 
one study did not find a significant difference in colonoscopy use by site of the 
tumor12.  Although this may be due to rectal cancer survivors being more likely to 
get sigmoidoscopies instead, studies of all colon exams found that colonoscopies 
comprised between 96% and 99% of all procedures performed, thus eliminating 
the possibility that sigmoidoscopies compensate for the underuse of 
colonoscopies.12, 14, 17  However, our finding of less frequent colonoscopies 
among rectal cancer survivors may reflect a selection bias.  Rectal cancer 
survivors are more likely than colon cancer survivors to get neoadjuvant therapy 
(chemotherapy or radiation), but our criteria of surgery within one month 
excluded many survivors who received neoadjuvant therapy.  Indeed, due to 
censoring, the proportion of participants who received neoadjuvant therapy fell 
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from 9% to 1% among colon cancer survivors, and from 30% to 0% among rectal 
cancer survivors.  Because it is possible that patients who receive neoadjuvant 
therapy are more likely to have a timely colonoscopy, it is also possible that 
those who were most likely to adhere to colonoscopy guidelines were excluded 
from the analysis. 
Survivors with severe comorbidities were less likely to receive a 
colonoscopy than survivors with more mild or no comorbidities.  Previous studies 
of Surveillance Epidemiology and End Results (SEER) Medicare fee-for-service 
populations have shown similar findings16, 18, although two studies14, 15 of 
managed care populations showed no effect of comorbidities on colonoscopy 
use.  The lower colonoscopy rate among survivors with more severe 
comorbidities suggests that if the presence of more severe comorbidities 
indicates patients with shorter expected life expectancies, physicians may be 
less likely to offer, and patients less likely to accept, surveillance colonoscopy.  
As well, survivors with more severe colonoscopies may be too frail to undergo 
colonoscopies. 
 Use of health services, specifically physician visits and cancer treatment, 
appears to be strongly related to colonoscopy use.  Seeing a primary care 
physician in the first year after diagnosis is associated with a higher likelihood of 
receiving a colonoscopy.  Similarly, those individuals who saw a medical 
oncologist or who received adjuvant chemotherapy were more likely to receive a 
colonoscopy.  Aside from one study that found that adjuvant chemotherapy use 
did not predict colonoscopy use among managed care enrollees14, health care 
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use remains understudied as a determinant of colonoscopy use.  Earle and 
Neville (2004) found that CRC survivors who were seen by both an oncologist 
and a primary care physician received the highest proportion of recommended 
ongoing preventive care (such as influenza vaccination and mammography) 
compared to survivors who saw a primary care physician alone, an oncologist 
alone, or neither a primary care physician or an oncologist.32  Visits to primary 
care physicians and medical oncologists may lead directly to referrals to 
colonoscopy.  The abstracted medical records and interviews did not collect data 
on referrals for colonoscopy, but future studies should examine the source of 
referrals to better understand which providers influence colonoscopy use.  If 
primary care providers are responsible for most referrals, improving coordination 
of care as patients move from acute cancer care to ongoing care may increase 
adherence to colonoscopy guidelines.  The Institute of Medicine has prioritized 
facilitating this transition, with the goal of improving ongoing care for cancer 
survivors.33    
Primary care visits, medical oncologist visits, and chemotherapy use may 
be indicators of access to high-quality care, in that survivors who have high-
quality ongoing care may be more likely to regularly consult a primary care 
physician (i.e., to have a medical home), to be referred for chemotherapy, and to 
be referred for timely surveillance colonoscopies.  Alternatively, prevention-
oriented survivors may be more likely to visit a primary care physician, to seek 
out adjuvant chemotherapy to reduce the risk of recurrence, and, similarly, to 
request a colonoscopy to reduce their risk of cancer.  Future longitudinal studies 
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should address survivors’ attitudes toward colonoscopy and CRC prevention and 
whether these attitudes affect colonoscopy use. 
Sociodemographic factors have minimal influence – race was the only 
statistically significant predictor of colonoscopy use, with white survivors being 
more likely to receive colonoscopies than black and Hispanic survivors, and 
survivors who are neither white, black, nor Hispanic black being most likely of all 
groups to receive timely surveillance colonoscopies.  Similar findings of racial 
disparities have been shown in some13, 16, 17, but not all12, 14, 18, 34, studies of 
sociodemographic influences on surveillance.  Adding this disagreement to the 
small proportion of survivors of other (non-black, non-Hispanic, and non-white) 
races in this study, and the heterogeneity of this group, racial disparities in 
colonoscopy use remains an area for further investigation. 
The strongest predictor of colonoscopy use was the population studied, 
with colonoscopy rates ranging from 20% to 58%.  Northern California had 
dramatically lower colonoscopy rates, even when controlling for survivor 
characteristics. Cooper et al. found geographic variation to a lesser degree with 
colonoscopy use, reporting a 1.5-fold difference in colonoscopy rates between 
the 9 SEER regions, about half the range observed in our study.31   Knopf et al. 
also reported large differences in colonoscopy rates between SEER regions.19  
Although Northern California’s low colonoscopy rate may reflect managed care 
penetration in that region, our results show that the utilization of colonoscopy in 
managed care organizations is actually more similar to utilization in the 
population-based Alabama and Los Angeles study centers and to the VA study 
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center than it is to Northern California.  The variation in rates between study 
centers may be due to either geographic variation in practice patterns or to 
differences in health care delivery systems.  Because the study centers are either 
geography-based, as in the North Carolina and Alabama sites, or based around 
a health care system, as in the VA and the managed care sites, it is difficult to 
disentangle these different possible influences on colonoscopy use in the present 
study.  
This study has limitations.  Inclusion criteria of surgery within 1 month after 
diagnosis could limit the findings.  However, similar results from the sensitivity 
analyses that permitted longer lags between diagnosis and surgery, as well as a 
sensitivity analysis that did not limit timing of the surgery, showed similar results.  
Second, this population was largely insured, albeit to different extents and with 
different insurance types.  Despite high levels of insurance, however, differences 
in surveillance colonoscopy use were observed in this study.  Third, the 
abstracted medical records did not include reasons for colonoscopy use, and it is 
possible that some colonoscopies were diagnostic instead of for routine 
surveillance.  This is unlikely, though, because Cooper et al.35 looked at 
indications for colonoscopy use among cancer survivors and found that 95% of 
colonoscopies performed were routine.  Finally, although medical record 
abstractors were instructed to request and to include all medical records ranging 
from 3 months before diagnosis to 15 months after diagnosis, it is not known 
whether all colonoscopy records were included, potentially resulting in an 
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undercount of colonoscopies.  It is also possible that colonoscopies were 
performed by physicians who did not contribute medical records for abstraction. 
Future studies of colonoscopy use among CRC survivors should examine 
more closely the referral process for colonoscopies in order to reduce clinically 
inappropriate variations in colonoscopy use across subgroups of survivors.  
Identifying which providers refer patients for colonoscopies is an important first 
step.  If referrals come from primary care physicians, this underscores the need 
for an improved transition from acute care to ongoing primary care.   
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Figure 4.1.  Flowchart of study participants 
 
 
 
Inception medical record cohort 
3678 patients with newly diagnosed CRC 
520 missing surgery or stage data 
520 stage IV 
528 had surgery > 1 month after diagnosis (censored)  
160 died within 14 months after surgery 
47 had colonoscopy within 60 days after surgery 
10 recurred (not after colonoscopy) 
1893  survivors 
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Table 4.1.  Characteristics of study sample (N=1893) 
 
 N % 
Age   
Less than 65 years 809 43 
65 years and older 1084 57 
Income   
Less than $50,000 749 40 
$50,000 and up 649 34 
Site of disease   
Colon 1543 82 
Rectum 324 17 
Stage    
I 530 28 
II 658 35 
III 699 37 
Comorbidities    
None 479 25 
Mild 842 45 
Moderate 341 18 
Severe 231 12 
Sex    
Male 1053  55 
Female 840  44 
Marital status   
Married 1153 61 
Not married 719 38 
Education   
Less than high school 854 45 
High school or more 974 51 
Race / ethnicity   
White 1273 67 
Black 289 15 
Hispanic 140 7 
Other 188 10 
Study center   
Northern California 385 20 
Alabama 308 16 
Los Angeles 301 16 
North Carolina 416 22 
VA hospitals 168 9 
Managed care 313 17 
Insurance   
Insured 1864 98 
Not insured  29 2 
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Speaks English   
Yes  1824 96 
No 59 3 
Saw a primary care provider   
Yes 1077 57 
No 813 43 
Saw a medical oncologist   
Yes 1691 89 
No 202 11 
Had adjuvant chemotherapy   
Yes 771 41 
No 1121 59 
Had adjuvant radiation   
Yes 103 5 
No 1777 94 
 
Note: Percentages may not add to 100 because of missing data.   
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Table 4.2.  Bivariate and multivariate relationships between patient 
characteristics and colonoscopy use within 14 months (N=1893)   
 Had 
colonoscopy  
N (%) 
 
Bivariate 
OR      p 
 
Multivariate 
OR      p 
All 751 (40)     
Age      
<65 years 352 (43) 1.32* 1.10-1.59 1.07  0.526 
65 years 
and older 
399 (37) 1.00 – 1.00           –             
Sex       
Male 419 (40) 1.01 0.84-1.22 0.85 0.144 
Female 332 (40) 1.00 – 1.00           –             
Site of tumor      
Colon 643 (41) 1.41* 1.09-1.81 1.51* 0.003 
Rectum 108 (33) 1.00 – 1.00           –             
Stage       
I 199 (37) 1.00 – 1.00           –             
II 275 (42) 1.13 0.93-1.37 0.99 0.930 
III 277 (40) 0.99 0.82-1.20 0.68* 0.019 
Comorbidities       
None 211 (44) 1.00 – 1.00           –             
Mild 352 (42) 1.17 0.98-1.41 0.99 0.933 
Moderate 124 (36) 0.84 0.66-1.07 0.79 0.135 
Severe 64 (28) 0.54* 0.40-0.74 0.52* 0.001 
Race / ethnicity      
White 512 (40)  1.00 – 1.00           –             
Black 109(38) 0.91 0.70-1.17 0.85 0.281 
Hispanic 44 (31) 0.68* 0.47-0.98 0.81 0.333 
Other 86 (46) 1.31 0.97-1.78 1.57* 0.010 
Education      
Less than 
high 
school 
341 (38) 1.00 – 1.07 – 
High school 
or more 
410 (41) 1.12 0.93-1.34 1.00 0.552             
Income      
<$50,000 381 (37) 0.77* 0.63-0.94 0.80 0.086 
≥$50,000 370 (43) 1.00 – 1.00           –             
Marital status      
Married 489 (42) 1.30* 1.07-1.57 1.11 0.342 
Not married 262 (36) 1.00 – 1.00           –             
Study center      
Northern 75 (19) 0.30* 0.23-0.39 0.46* 0.000 
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 Had 
colonoscopy  
N (%) 
 
Bivariate 
OR      p 
 
Multivariate 
OR      p 
California 
Alabama 113 (37) 0.86 0.67-1.11 1.09 0.650 
Los Angeles 142 (47) 1.45* 1.13-1.85 1.70* 0.003 
North 
Carolina 
238 (57) 2.46* 1.97-3.06 2.49* 0.000 
VA hospitals 68 (40) 1.04 0.75-1.43 1.57* 0.037 
Managed 
care 
115 (37) 1.00 – 1.00           –             
Saw a primary 
care provider 
     
Yes 465 (43) 1.40* 1.16-1.68 1.27* 0.022 
No 286 (35) 1.00 – 1.00           –             
Saw a medical 
oncologist 
     
Yes 695 (41) 1.82* 1.32-2.51 1.52* 0.022 
No 56 (28) 1.00 – 1.00           –             
Had adjuvant 
chemotherapy 
     
Yes 360 (47) 1.63* 1.35-1.96 1.73* 0.000 
No 391 (35) 1.00 – 1.00           –             
 
Note: * = p <0.05, OR = odds ratio, 95% CI = 95% confidence interval.  
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V.  PREDICTORS OF UNDERUSE AND OVERUSE OF COLONOSCOPY 
AMONG COLORECTAL CANCER SURVIVORS IN NORTH CAROLINA 
 
5.1  Abstract 
 
Objectives:  Because colorectal cancer survivors are at elevated risk for both 
local recurrences and second primary cancers, clinical practice guidelines 
recommend ongoing testing (surveillance) for colorectal cancer.  However, many 
colorectal cancer survivors do not get adequate surveillance, while other 
colorectal cancer survivors get surveillance too often.  We investigated predictors 
of underuse and overuse of surveillance colonoscopy among colorectal cancer 
survivors. 
 
Methods:   176 colorectal cancer survivors from North Carolina who were 
diagnosed 4 years earlier completed a telephone interview that measured 
colonoscopy use since curative surgery for colorectal cancer. 
 
Results:   Within three years of diagnosis, 18% of colorectal cancer survivors had 
no colonoscopies, and 21% had too many.  Only 61% received the appropriate 
number of colonoscopies.  Survivors with moderate or more severe comorbidities 
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were less likely to have any colonoscopies than survivors with no comorbidities.  
Few variables were associated with colonoscopy overuse. 
 
Conclusions:  Underuse and overuse of routine colonoscopy are common among 
colorectal cancer survivors.  With more than one third of participants receiving 
care that is not in accordance with guidelines, surveillance colonoscopy is not 
benefiting enough colorectal cancer survivors.  Some underuse appears to be 
due to comorbidity.   A better understanding of underuse and overuse could 
improve outcomes and reduce costs. 
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5.2  Introduction 
 
Clinical practice guidelines recommend that survivors of colorectal cancer 
(colorectal cancer) receive ongoing routine surveillance for colorectal cancer with 
colonoscopy.1, 2  Undergoing colonoscopies less often than recommended may 
lead survivors to miss opportunities to detect colorectal cancers (or precancerous 
polyps) at a point when treatment may be more successful.  Unfortunately, 
colorectal cancer survivors often get less surveillance than recommended by 
guidelines.  Three years after diagnosis, 24% to 40% do not receive colorectal 
cancer surveillance 3-5, and 20% to 35% do not receive any colorectal cancer 
surveillance within 5 years.4-6   
At the same time, overuse of colonoscopy carries the increased risk of 
bleeding and tearing from the procedure, and if little clinical benefit arises from 
more frequent colonoscopies, the potential harms may outweigh the potential 
benefits.  In addition, from a resource perspective, overuse of colonoscopy may 
strain the capacity of colonoscopy providers, and longer wait times may delay 
care for patients who need it most.  Studies suggest that some colorectal cancer 
survivors are having surveillance colonoscopies more frequently than 
recommended.  Two studies found that the median time between first and 
second surveillance colonoscopies was between 13 and 14 months, an interval 
shorter than any guideline recommends.4, 7  Another study using Surveillance 
Epidemiology and End Results (SEER) Medicare data found that 11% of 
colorectal cancer survivors had colonoscopies annually or more frequently.8   
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Improving adherence to clinical practice guidelines entails understanding 
which survivors are most likely to underuse and overuse colonoscopy and 
addressing reasons for nonadherence.  Prior studies of predictors of underuse 
identified clinical and demographic characteristics of colorectal cancer survivors 
who are less likely to receive colorectal cancer surveillance.  These survivors 
include those who have rectal cancer (as opposed to colon)3, 5, 6, 9, are younger,3-
6, 8, 9 and are white 3, 5, 10, although the evidence for race is inconsistent. 4, 6, 9   We 
aimed to clarify how these factors contribute not just to underuse but to overuse 
of colonoscopy as well.   
Aside from clinical and demographic predictors of underuse and overuse 
of colonoscopy, we aimed to establish whether access to care and use of health 
care affect colonoscopy use.  Visiting a primary care physician appears to 
increase uptake of preventive services by cancer survivors.11  The Institute of 
Medicine has suggested that much of survivors’ poor ongoing care is due to poor 
continuity between cancer care and ongoing preventive care.12  Because 
adherence to colonoscopy guidelines may be an issue of access to care, we 
investigated whether survivors who visited a primary care provider would be 
more likely to have routine surveillance colonoscopies.  Similarly, because those 
who underwent colorectal cancer screening before diagnosis with colorectal 
cancer also may have better access to surveillance colonoscopy (as well as a 
history of preventive behavior), we investigated whether they may be more likely 
to undergo routine colonoscopies.  We hypothesized that these groups with 
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presumably better access to ongoing care may also get overly frequent 
colonoscopies.   
 
5.3  Method 
 
Sample 
Participants in this study came from the Cancer Care Outcomes Research 
and Surveillance (CanCORS) consortium, a multi-center cohort study of 
colorectal and lung cancer patients.  The CanCORS population and procedures 
are described more fully elsewhere.13   This study is limited to colorectal cancer 
patients from North Carolina, which encompassed all colorectal cancer patients 
ascertained in 33 counties in the state cancer registry.  CanCORS participants 
from the North Carolina site who were originally diagnosed with stage I-III 
colorectal cancer and were alive without metastasis 4 years after diagnosis were 
included in the present analysis (Figure 5.1).  Participants who were undergoing 
treatment for their primary cancer were ineligible, as were participants who were 
unable to have a colonoscopy (i.e., did not have enough or any remaining colon) 
or whose colonoscopy was performed in response to symptoms/abnormal tests 
(because the recommended surveillance intervals are different).  This study was 
approved by the University of North Carolina Institutional Review Board. 
 
Data sources 
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Data for each participant came from three sources.  First, abstracted 
medical records provided data on clinical and characteristics, disease status, 
demographic characteristics, and diagnostic procedures.  Second, follow-up 
telephone interviews conducted approximately 1 year after diagnosis elicited 
information on sociodemographic characteristics.  When sociodemographic 
characteristics conflicted between the two sources, the interview was considered 
the gold standard.  Finally, for this study, an additional telephone interview was 
conducted 4 years after diagnosis with participants from the North Carolina 
CanCORS site.  These follow-up interviews assessed colorectal cancer 
surveillance, primary care use, and past use of colorectal cancer screening.    
 
Measures 
Outcome.  The outcome for this study was appropriate use of routine 
colonoscopy since surgery, determined by patient report using a previously 
validated measure that was administered during the interview.14  We asked 
patients the reason for obtaining each colonoscopy; responses were coded as 
part of a routine exam or checkup, because of a symptom, follow-up of an earlier 
abnormal test, or not sure.  For each colonoscopy, participants were asked to 
report the month and year of the colonoscopy.  Using these responses, we 
created a 3-level measure of appropriateness (underuse, appropriate use, or 
overuse) based on the guidelines in effect since participants were diagnosed with 
colorectal cancer.1, 15-23  We conservatively interpreted guidelines such that at 4 
years after diagnosis, having had no colonoscopies would be underuse; having 
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had 1 colonoscopy would be appropriate; and having had 2 colonoscopies was 
considered appropriate if the second colonoscopy occurred after 3 years, but 
overuse if it occurred before 3 years after surgery.  Finally, having had 3 or more 
colonoscopies was considered overuse.   
Predictors.  Predictors of colonoscopy use were demographic and clinical 
characteristics and health care utilization.  Demographic characteristics included 
age and sex, which came from abstracted medical records, and race, education, 
income, and insurance status, which came from the 1-year follow-up interviews.  
Clinical variables were site of tumor (colon or rectum), stage at diagnosis, and 
presence and severity of comorbidities, which were determined from abstracted 
medical records.  Comorbidities were categorized as none, mild, moderate, or 
severe according to the Adult Comorbidity Evaluation (ACE-27) index.24-26  Stage 
at diagnosis was determined using collaborative staging if available.  If 
unavailable, stage was determined from the registry or medical records.  
Additionally, having visited a primary care physician and having had colorectal 
cancer screening before diagnosis were determined from the 4-year interview.  
The screening question was a validated measure created by Vernon et al.14  
Finally, in order to determine whether survivors had an alternate test instead of 
colonoscopies, the 4-year interview included a question about whether 
participants had undergone sigmoidoscopies since diagnosis, using an item 
previously validated to assess sigmoidoscopy for colorectal cancer screening.14 
All variables were dichotomous, expect age, which was defined as a continuous 
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variable in 10-year increments, and income, which was defined as a continuous 
variable in $10,000 increments. 
 
Analyses   
We imputed missing data on independent variables using an iterative 
multivariable regression procedure in Stata.27, 28  Dichotomous predictors that 
had less than 10% of the sample in one of the two categories were excluded 
from the analyses.  We used bivariate multinomial logit models to model 
predictors of underuse, appropriate use, and overuse of routine colonoscopy, 
followed by a multivariable multinomial logit model with all predictors.  Because 
appropriate use and overuse may have the same relationships with the 
predictors, we combined these two categories to create a dichotomous measure 
of underuse of routine colonoscopies after surgery (compared with any use) as a 
secondary analysis.  We modeled underuse of colonoscopy in bivariate logit 
models and a single multivariable logit model.29  The significance of individual 
predictors for each analysis was determined with Wald χ2 tests29; we present 
odds ratios and 95% confidence intervals for these analyses. 
 
5.4  Results 
 
Colorectal cancer survivors were contacted between April 2007 and May 
2008; 176 met the eligibility criteria (Figure 5.1).  Participants were interviewed a 
mean of 45 months since their diagnosis (standard deviation [s.d.] = 2.3 months) 
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and 44 months since surgery for their cancer (s.d. = 2.5 months).  Patient 
characteristics are presented in Table 5.1.    Eighty-two percent were white, and 
the mean age was 64 (s.d. = 13 years).  Eighty percent had cancer in their colon.  
The month and date of colonoscopy use was missing for 48% of participants and 
was imputed as July 1.  Because of inadequate variation, we dropped the 
following variables from analyses: having seen a primary care provider, being 
insured, and sigmoidoscopy since surgery.  Moderate and severe comorbidities 
were collapsed into a single category due to small cell sizes.   
Sixty-one percent of participants had the appropriate number of routine 
colonoscopies;18% had too many, and 21% had too few, colonoscopies.  
Characteristics of participants and their level of colonoscopy use are shown in 
Table 5.2.  In bivariate analyses, participants who had moderate or severe 
comorbidities were more likely underuse colonoscopies than those with no 
comorbidities (OR = 4.10, 95% CI: 1.74 – 9.68).  Also, the likelihood of 
underusing colonoscopy increased with age (OR = 1.74, 95% CI: 1.17 – 2.59). 
No variables predicted overuse of colonoscopy. 
In multivariable analysis, participants with moderate or severe 
comorbidities were more likely to underuse colonoscopies than get the 
appropriate amount, compared to those who had no comorbidities (OR = 9.36, 
95% CI: 1.81–48.43).  (Table 5.3)  None of the other demographic, clinical, or 
health services variables were associated with underuse.  Further, none of the 
variables were associated with routine colonoscopy overuse. 
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In bivariate analyses of the dichotomous variable (i.e., having underused 
colonoscopy or not), the likeliness of underusing colonoscopy increased with age 
(OR = 1.84, 95% CI: 1.24-2.72). Having moderate or severe comorbidities was 
associated with a higher likelihood of not undergoing any colonoscopies (OR = 
4.10, 95% CI: 1.80–9.34).  In multivariate analyses, survivors who had moderate 
or severe comorbidities were more likely to not undergo colonoscopies than 
survivors with no comorbidities (OR = 10.12, 95% CI: 2.06–49.84).  (Table 5.4) 
 
5.5  Discussion 
 
Guidelines recommend that colorectal cancer survivors have routine 
colonoscopies to detect new or recurring lesions.  However, prior studies suggest 
that these guidelines are often not followed:  some survivors have colonoscopies 
more frequently, and other less often, than recommended.  Both underuse and 
overuse of colonoscopy for surveillance can have negative consequences.  
Underuse may result in tumors being detected only after they become 
symptomatic, at which point they may be more difficult to treat.  Having more 
colonoscopies than recommended may not bring any clinical benefit, at the risk 
of bleeding and tearing from the procedure.  In addition, overuse may strain the 
capacity of colonoscopy providers, which may result in delayed colonoscopies for 
those who may benefit more from the procedure. 
To date, studies on the appropriate use of surveillance by survivors have 
been limited by their generalizability (i.e., clinical samples) or their focus on 
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underuse, rather than overuse.  We studied underuse and overuse in a diverse 
population-based sample of recently diagnosed colorectal cancer survivors.  We 
found that only 61% of survivors (N=107) received the appropriate number of 
colonoscopies; 18% (N=32) reported receiving no colonoscopy during the 4 
years after diagnosis, and 21% (N=37) had more than recommended by 
guidelines.  The overuse and underuse seen in this study concur with the pattern 
of simultaneous overuse and underuse of colonoscopy in prior studies.4, 7, 8   With 
more than one third of participants receiving care that is not in accordance with 
guidelines, surveillance colonoscopy is not benefiting enough colorectal cancer 
survivors. 
We examined demographic, clinical, and health care characteristics, many 
of which have been shown to be significant predictors of colonoscopy use among 
colorectal cancer survivors in prior studies. 3-6, 8-10  However, despite considering 
a broad range of survivor factors, we found only one fairly consistent significant 
correlate of underuse of surveillance colonoscopies: severity of comorbidities.    
Survivors who had moderate or severe comorbidities were less likely to have had 
any colonoscopies than survivors with no comorbidities.  This result was found 
when colonoscopy use was categorizes as underuse, appropriate use, and 
overuse, as well as when colonoscopy use was categorized as underuse 
compared to any use.  Comorbidities have been shown to be related to 
colonoscopy use in some prior studies.  In studies of colorectal cancer survivors 
using Surveillance Epidemiology and End Results (SEER) Medicare data, 
survivors with more severe comorbidities underwent fewer colonoscopies3, 9, 
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although two studies of managed care populations6, 7 found no effect of 
comorbidities on colonoscopy use.  Because these survivors are less healthy, 
undergoing fewer colonoscopies may actually be appropriate.  Future studies 
should address whether survivors with more severe comorbidities are actually 
too frail to undergo colonoscopy, or whether they should be offered (and should 
undergo) colonoscopies according to current guidelines. 
Aside from comorbidities, no survivor factors were related to underuse of 
colonoscopy, and none were related to overuse of colonoscopy.  Without being 
able to determine why survivors do not receive appropriate surveillance, it will be 
difficult to develop strategies targeted at clinicians, patients, or health care 
systems that might improve use of colonoscopy.  Future studies may need to 
consider psychological or cognitive factors, such as fear of getting cancer again 
or perceived barriers to colonoscopy use. 
There are several limitations in our study.  First, it is possible that we lack 
the statistical power to detect differences.  For example, with 176 participants, an 
odds ratio of 7.46 would be required for the effect of race/ethnicity to be 
significant in the multinomial logit model.  If the estimates from this study 
accurately reflect population means, the sample size would have to be between 
440 and 525 to be able to detect the effects of age, gender, education, and race 
and ethnicity on colonoscopy underuse.  Second, because 48% of the sample 
did not remember the month of at least one of their colonoscopies, the imputed 
colonoscopy date may have led to misclassification of their colonoscopy use, 
which in turn may have biased the results.  We conducted sensitivity analyses in 
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which 1) all colonoscopy dates with missing months were coded as the earliest 
possible date and 2) all colonoscopy dates with missing months were coded as 
the latest possible date.  The results were generally unchanged.  Similarly, 
survivors may have had difficulty remembering the timing of colonoscopies after 
surgery or the reason for the colonoscopies, either of which could lead to 
misclassification of this variable.  Third, both the cross-sectional nature of the 
analyses and the use of measures of colonoscopy use that have not been 
previously validated among survivors limited the internal validity of this study.  
Fourth, due to lack of variation, we were unable to include having seen a primary 
care provider, being insured, and sigmoidoscopy since surgery as predictors of 
colonoscopy use.  Fifth, we relied on self-report of routine colonoscopy.  
Although a recent meta-analysis found that self-report has good sensitivity (0.82) 
and specificity (0.85) for screening colonoscopy,30 the meta-analysis did not 
address surveillance colonoscopy.  Finally, the study was conducted in a single 
state, which limits generalizability of our findings.     
Despite these limitations, this study used a diverse population to study 
both underuse and overuse of colonoscopy.  We found that approximately a fifth 
of participants had not received any colonoscopies since surgery, and another 
fifth of participants received colonoscopies too often.  Both underuse and 
overuse may be harmful to survivors, and better adherence to clinical practice 
guidelines may improve outcomes for survivors. The determinants of poor 
adherence to guidelines are still unknown.   Larger, prospective studies of 
colorectal cancer survivors, preferably using medical records or administrative 
   90 
data to determine colonoscopy use, may shed more light on what causes 
survivors to overuse or underuse routine colonoscopies.  
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Figure 5.1.  Flowchart of study participants 
 
 
 
 
736 North Carolina CanCORS CRC participants completed 1-year interview 
316 not yet at 3.5 years from diagnosis 
74 refused, unreachable, incapable 
18 deceased  
13 in treatment 
14 had colectomy 
23 had metastasis or new primary 
 
176 participants in analytic sample 
13 no surgery date 
16 no stage 
8 stage IV 
7 stage 0 
13 had any nonroutine colonoscopies 
45 did not report colonoscopy use 
278 completed 4-year interview 
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Table 5.1.  Sample characteristics (N=176) 
 
Characteristic % 
Age less than 65 54 
Male 47 
High school or more education 51 
Married 63 
White (vs. nonwhite) 82 
Income less than $50,000 51 
Insured 95 
Colon cancer (vs. rectal 
cancer) 
80 
Stage at diagnosis  
I 36 
II 27 
III 37 
Comorbidities  
None 29 
Mild 43 
Moderate 18 
Severe 10 
Had colorectal cancer 
screening 
48 
Has seen primary care 
provider 
96 
Had a sigmoidoscopy since 
surgery 
3 
Note: colorectal cancer = colorectal cancer
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Table 5.2.  Characteristics of participants who underuse, appropriately use, or 
overuse routine colonoscopies. (N=176) 
 
Underuse 
N (%) 
Appropriate 
use  
N (%) 
Overuse 
N (%) 
Age     
Less than 65 year 7 (4) 53 (30) 21 (12) 
65 years or older 25 (14) 54 (31) 16 (9) 
Gender    
Male 19 (11) 46 (26) 18 (10) 
Female 13 (7) 61 (35) 19 (11) 
Education    
Less than high school  12 (8) 49 (31) 16 (10) 
High school or more 18 (11) 46 (29) 17 (11) 
Marital status    
Married 17 (10) 67 (38) 26 (15) 
Not married 15 (9) 39 (22) 11 (6) 
Race/ethnicity    
White  28 (16) 82 (47) 28 (16) 
Nonwhite 4 (2) 4 (2) 9 (5) 
Income    
Less than $50,000 9 (6) 45 (32) 18 (13) 
$50,000 or more 14 (10) 41 (29) 15 (11) 
Site of tumor: colon     
Colon 21 (14) 73 (48) 28 (18) 
Rectum 4 (3) 19 (12) 8 (5) 
Stage at diagnosis    
I 9 (5) 36 (22) 14 (8) 
II 10 (6) 26 (16) 9 (5) 
III 11 (7) 36 (22) 14 (8) 
Comorbidities    
None 2 (1) 28 (18) 16 (10) 
Mild 10 (6) 46 (29) 12 (8) 
Moderate or severe 16 (10) 21 (13) 8 (5) 
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Table 5.3.  Multivariable multinomial logit predictors of underuse and overuse of 
routine colonoscopy (N = 176) 
 Underuse 
OR  (95% CI) 
 
p 
Overuse 
OR  (95% CI) 
 
p 
Age (in 10 years) 1.53  (0.93-2.52) 0.095 0.81  (0.59-1.11) 0.192 
Gender     
Male 2.51  (0.87-7.19) 0.087 1.05  (0.47-2.34) 0.913 
Female  1.00         –                       – 1.00         –            – 
Education     
High school or more  2.61  (0.87-7.82) 0.086 1.10  (0.40-3.02) 0.861 
Less than high school  1.00         –                       – 1.00         –            – 
Marital status     
Married 0.71  (0.24-2.09) 0.539 1.29  (0.50-3.32) 0.602 
Not married  1.00         –                       – 1.00         –            – 
Race/ethnicity     
White  3.25  (0.79-13.43) 0.104 1.07  (0.40-2.83) 0.894 
Nonwhite 1.00         –             – 1.00         –            – 
Income (in $10,000) 0.88  (0.72-1.06) 0.170 0.99  (0.85-1.14) 0.844 
Site of tumor: colon      
Colon 1.32  (0.29-5.95) 0.718 0.86  (0.3-2.42) 0.770 
Rectum  1.00         –                       – 1.00         –            – 
Stage at diagnosis     
I  1.00         –            – 1.00         –            – 
II 1.66  (0.48-5.76) 0.425 0.78  (0.26-2.33) 0.658 
III 1.79  (0.55-5.79) 0.330 0.91  (0.35-2.35) 0.851 
Comorbidities     
None  1.00         –                       – 1.00         –            – 
Mild 2.78  (0.52-14.82) 0.232 0.53  (0.19-1.47) 0.221 
Moderate or severe 9.36 (1.81-48.43) 0.008 0.75  (0.23-2.44) 0.635 
Had screening before 
diagnosis 
    
Yes 1.06  (0.39-2.84) 0.911 1.00  (0.45-2.21) 0.992 
No  1.00         –                       – 1.00         –            – 
 
Note: Multinomial logit model compared underuse to appropriate use of 
colonoscopy and overuse to appropriate use of colonoscopy.   OR = odds ratio, 
95% CI = 95% confidence interval.  
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Table 5.4.  Multivariable logit predictors of not having had any (vs. having had 
any) colonoscopies since surgery (N = 176) 
Characteristic Underuse 
OR 
 
95% CI 
 
p 
Age (in 10 years) 1.61 0.98-2.63 0.059 
Gender    
Male 2.49 0.88-7.03 0.085 
Female 1.00 – – 
Education    
High school or more  2.56 0.89-7.39 0.082 
Less than high school 1.00 – – 
Marital status    
Married 0.68 0.24-1.94 0.465 
Not married 1.00 – – 
Race/ethnicity    
White  3.21 0.79-12.99 0.102 
Nonwhite 1.00 – – 
Income (in $10,000) 0.88 0.73-1.06 0.168 
Site of tumor     
Colon 1.37 0.32-5.90 0.675 
Rectum 1.00 – – 
Stage at diagnosis    
I 1.00 – – 
II 1.75 0.52-5.92 0.370 
III 1.83 0.57-5.86 0.309 
Comorbidities    
None 1.00 – – 
Mild 3.23 0.64-16.34 0.157 
Moderate or severe 10.12 2.06-49.84 0.004 
Had screening before 
diagnosis 
   
Yes 1.06 0.40-2.78 0.905 
No 1.00 – – 
 
OR = odds ratio, 95% CI = 95% confidence interval.   
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VI. THE ASSOCIATION OF HEALTH BELIEFS AND INTENTIONS AMONG 
SURVIVORS OF COLORECTAL CANCER 
 
6.1  Abstract 
 
Objectives:  Because colorectal cancer survivors are at risk for both local 
recurrences and second primary cancers, clinical practice guidelines recommend 
ongoing testing (surveillance) for colorectal cancer.  However, survivors often do 
not receive colorectal cancer surveillance.  We used the Health Belief model to 
predict intentions to obtain routine colonoscopies among colorectal cancer 
survivors.  
 
Methods:   234 colorectal cancer survivors from North Carolina who were 
diagnosed four years earlier completed a telephone interview that measured 
health beliefs, past preventive behaviors, and intentions to have a routine 
colonoscopy in the next five years.  Intentions were assessed as desire to have a 
colonoscopy and expectation of having a colonoscopy. 
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Results:  Greater perceived likelihood of colorectal cancer (OR = 1.76 for desire 
and OR = 3.76 for expectation, p-values <0.01) and lower perceived barriers to 
getting a colonoscopy (OR = 0.40 for desire, p <0.01) were correlated with 
greater intentions to have a colonoscopy.  Survivors who already had a 
colonoscopy since diagnosis also had greater intentions to have a colonoscopy 
in the future (OR = 5.72 for desire, p<0.01 and OR = 22.14 for expectation, 
p<0.05).   
 
Conclusions:  As predictors of surveillance intentions, perceived likelihood of 
colorectal cancer and perceived barriers to colorectal cancer are important 
targets for further study and intervention to increase colorectal cancer 
surveillance among survivors.  Other health beliefs were unrelated to intentions, 
suggesting that the health beliefs of colorectal cancer survivors and 
asymptomatic adults may differ due to the experience of cancer. 
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6.2  Introduction 
 
With an estimated 150,000 new cases in 2008, colorectal cancer is the 
third most common cancer found in men and women in the US.1  Because 
colorectal cancer survivors are at risk for both local recurrences and second 
primary cancers,2 clinical practice guidelines recommend ongoing testing 
(surveillance) for colorectal cancer.  Although recommendations have differed 
somewhat over the last decade regarding the specific test (e.g., colonoscopy, 
sigmoidoscopy) and frequency of colonoscopies, all of the various guidelines 
recommend colorectal cancer surveillance to reduce the risk of mortality from 
recurrence and second primary lesions.3-11 In 2006, multiple organizations 
reached consensus that colorectal cancer survivors should get routine 
colonoscopies 1 and 3 years after surgery, and then every 5 years after surgery.4   
Regardless of the guideline used, colorectal cancer survivors do not get 
adequate surveillance.  Three years after diagnosis, 24% to 40% do not receive 
colorectal cancer surveillance,12-14 and 20% to 35% do not receive any colorectal 
cancer surveillance within 5 years.13-15  Prior studies have identified clinical and 
demographic characteristics of colorectal cancer survivors who are less likely to 
receive colorectal cancer surveillance, including those who have rectal cancer 
(as opposed to colorectal cancer),12, 14-16 are younger,12-17 and are white,12, 14, 18 
although the evidence for race is inconsistent.13, 15, 16  Although these studies 
identify survivors who are more or less likely to receive guideline-concordant 
surveillance, these factors are not mutable.  To develop effective strategies to 
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increase surveillance, it is important to identify potentially modifiable factors that 
can direct the content of an intervention.   
The Health Belief Model (HBM) posits that preventive health behavior with 
respect to a given disease is more likely among individuals who have higher 
perceived likelihood of getting the disease, higher perceived severity of the 
disease, fewer perceived barriers to prevention, more perceived benefits of 
prevention, higher self-efficacy, and who experience more cues to taking 
action.19  HBM constructs have been used extensively to both predict screening 
behavior (including colorectal cancer) and design interventions to increase 
screening.20-28    However, HBM has not been applied to colorectal cancer 
surveillance.  This is critical because experiencing colorectal cancer may change 
key elements of the HBM, including perceived likelihood of getting subsequent 
colorectal cancer, perceived benefits of colonoscopy, and cues to action.   Thus, 
it is important to extend lessons from screening of asymptomatic individuals in 
the general population to surveillance of cancer survivors. 
Our study investigated the relationship of health beliefs to intentions to 
receive surveillance colonoscopy 5 years following diagnosis in a cohort of 
colorectal cancer survivors.   Our primary hypotheses were that higher perceived 
likelihood of colorectal cancer, more perceived benefits to colonoscopy, fewer 
perceived barriers to colonoscopy, greater self-efficacy, and more cues to action 
would be associated with intention to have colonoscopy in the next 5 years 
(Figure 6.1).  We had 3 secondary hypotheses.  First, poor continuity of care is 
associated with underuse of preventive care among survivors.29-31  Because 
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having a primary care physician may enhance continuity, we hypothesized that 
having seen a primary care physician since being diagnosed would be 
associated with greater intentions to receive colonoscopy in the future.  Second, 
we hypothesize that survivors who had undergone colorectal cancer screening 
before their colorectal cancer diagnosis would have greater intentions to have a 
surveillance colonoscopy than those who did not.  Finally, we hypothesized that 
having had surveillance colonoscopy would be associated with greater intentions 
to have colonoscopy in the future. 
 
6.3  Methods 
 
Sample 
Data come from the Cancer Care Outcomes Research and Surveillance 
(CanCORS) Consortium, a national, population-based cohort study of lung and 
colorectal cancer. Detailed descriptions of CanCORS have been published 
elsewhere.32, 33  Briefly, patients diagnosed with colorectal cancer or lung cancer 
from May 2003 through October 2005 were identified from cancer registries at 8 
study sites across the country. Eligible participants for the present study included 
CanCORS participants from 33 counties in North Carolina who completed 
baseline and 1-year interviews, were diagnosed with stage I-III colorectal cancer, 
were alive without metastasis, and were not undergoing treatment for their 
original cancer.  Participants who were unable to have colonoscopies (i.e., did 
not have enough remaining colon) were not eligible to participate.   
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Data sources 
Data for this study came from three sources.  First, for eligible participants 
providing informed consent, medical record audits were conducted by abstractors 
trained by a central CanCORS team to ascertain cancer-related medical visits 
and procedures.  Specifically, data on clinical characteristics, disease status, vital 
status, demographics, treatments, diagnostic procedures, and participation in 
clinical trials were collected.  Second, baseline interviews with participants were 
conducted approximately 4 months after diagnosis.  These interviews elicited 
information about cancer care decision making, symptoms, satisfaction with care, 
demographics, and other topics for which survivors are an important source of 
information.  Finally, follow-up interviews were conducted approximately four 
years after diagnosis.  These follow-up interviews assessed colorectal cancer 
surveillance, health beliefs, and intentions to have colonoscopy in the future.   
This study was approved by the University of North Carolina Institutional Review 
Board. 
 
Dependent variables 
The outcome for this study was intention to receive a colonoscopy in the 
next 5 years.  Based upon current guidelines, which were in place at the time of 
the interviews, all participants eligible for the follow-up interviews were due for at 
least 1 colonoscopy in the next 5 years.  The interviewer described 
colonoscopies and then asked 3 questions about the participant’s intention to 
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receive a colonoscopy in the next 5 years, operationalized as desire, planning, 
and expectation to have colonoscopies.  To assess desire to have a 
colonoscopy, the item asked “How much do you want to have a colonoscopy in 
the next 5 years?”, with response options ranging from 1 = “not at all” to 5 = 
“want to very much.”  The planning measure was worded as “Do you plan to 
have a colonoscopy in the next 5 years?”, and included a yes/no response 
option.  Expectation of having a colonoscopy was measured as “How likely are 
you to have a colonoscopy in the next 5 years?”, with response options ranging 
from 1 = “extremely unlikely” to 5 = “extremely likely.”   
 
Health belief variables 
Perceived likelihood.  On a scale from 1 (no chance) to 5 (certain to get it), 
we asked subjects “Assuming you do NOT get colonoscopies at regular intervals, 
what do you think is your chance of getting cancer in your colon or rectum again 
in your lifetime?”  The wording was designed to include both local recurrences 
and second primary colorectal cancers, both of which are targets of surveillance 
colonoscopy.   
Perceived benefits and barriers.  Perceived benefits of, and barriers to, 
colonoscopy were assessed by adapting validated measures for colorectal 
cancer screening (alpha for benefits = 0.70 and alpha for barriers = 0.77).26  The 
9 benefit items asked about the effectiveness of colonoscopy and the benefits of 
early detection.  The barriers measures included 5 items that addressed 
concerns about undergoing colonoscopy (including negative results) and 
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structural barriers (e.g., cost, transportation).  The adaptations from the original 
measures reflect differences between screening colonoscopy for asymptomatic 
adults and surveillance colonoscopy for colorectal cancer survivors.  The 5-point 
response scale for each item ranged from 1 (strongly disagree) to 5 (strongly 
agree).  Perceived benefits and perceived barriers each formed a reliable scale 
(Cronbach’s alpha = 0.82 and 0.82, respectively), and each set of items was 
combined into an averaged summary measure. 
  Self-efficacy.  Based upon a measure of self-efficacy for blood donation,34 
participants were asked how confident they were that they could get a 
colonoscopy when they are due for one (1 = “not at all confident” to 5 = 
“extremely confident.”   
Cues to action.  Four items assessed whether, since having surgery, any 
primary care physician, other physician, other non-physician health care provider, 
or person who is not a healthcare provider has recommended that the participant 
receive routine colonoscopies; each item was scored as 1 (yes) or 0 (no).   
 
Preventive behavior variables 
Screening history.  The interviewer asked participants whether they had 
colorectal cancer screening before being diagnosed with colorectal cancer using 
measures created and tested by Vernon et al., with a yes/no response option.35   
Visit to primary care provider.  The interviewer asked participants whether 
they had seen a primary care provider since being diagnosed with colorectal 
cancer (1=yes, 0=no).   
   107 
 
Surveillance colonoscopy use. The interviewer asked participants if they 
had any colonoscopies in the past three years since diagnosis, using a measure 
created and tested by Vernon et al.35  This was coded as 1 (yes) or 0 (no). 
 
Covariates 
Other predictors of colonoscopy intentions included age, sex, site of the 
tumor (colon or rectum), stage at diagnosis, and severity of comorbidities, which 
came from the abstracted medical records.  Severity of comorbidities was 
assigned as none, mild, moderate, or severe using the Adult Comorbidity 
Evaluation (ACE-27) index.36-38 Stage at diagnosis was determined using 
collaborative staging if available.  If unavailable, stage was determined from the 
registry or medical records.  Additionally, education (less then high school or 
more than high school), income level (continuous in $10,000 increments, and 
whether or not participants had insurance (yes/no) were determined from the 1-
year follow-up interview.    
 
Analysis 
We imputed missing data using an iterative multivariable regression 
technique in Stata.39, 40   For all analyses, data were analyzed using two-tailed 
tests, with p values less than 0.05 considered significant, in Stata.41 Statistical 
significance of predictors for all logit and ordered logit tests was determined 
using Wald χ2 tests.42 
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Descriptive analyses.  We measured the associations between each 
intention measure and health beliefs, use of primary care, history of screening, 
and use of surveillance using bivariate models.  We used ordered logit models 
for the 5-category desire and expectation variables and a logit model for the 2-
category planning variable.  We presented results as odds ratios with confidence 
intervals and p values.  
 Main analyses.  We planned to test the presence of interactions between 
health beliefs and clinical characteristics by including all possible interactions in 
the logit and ordered logit multivariable models; however, the models would not 
converge.  Therefore, a model-building strategy was employed to test the 
interaction of each of the 8 health beliefs on each of the 2 clinical characteristics 
by conducting multiple regression analyses as follows.  We regressed each 
intention measure on a single health belief, a single clinical characteristic, and 
the interaction of the health belief and clinical characteristic, using logit, ordered 
logit, or linear regression models, depending on the functional form of the health 
belief variable.  Statistically significant interaction terms, established with a joint 
Wald χ2 test of significance for logit and ordered logit model42 and with joint F 
tests for linear regression models,43 were then included in the multivariable 
model.  Statistically significant interactions were later included in the main 
analyses.      
 Using ordered logit models for the 5-category desire and expectation 
variables and a logit model for the 2-category planning variable, we assessed 
predictors of each intention measure.  All independent variables and any 
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identified interaction terms were then included in the multivariable regression 
model for each intention measure, and we reported odds ratios, 95% confidence 
intervals, and p values.  
 
6.4  Results 
 
Description of the sample 
Two hundred seventy-eight participants completed  the 4-year interview 
between April 2007 and May 2008 (Figure 6.2).  Of these, 52 were excluded from 
the analysis due to being stage IV or stage 0 (N=31), not having had surgery 
(N=13), or not having responded to the intention questions (N=8), yielding a final 
sample of 226 participants.  Participants were interviewed a mean of 45 months 
since diagnosis (standard deviation [s.d.] = 2.3 months) and a mean of 44 
months since their primary cancer surgery (s.d. = 2.5 months).  Most (80%) 
survivors had colon cancer; 53% were female; and 78% were white.  Virtually all 
(96%) had visited a primary care physician since their diagnosis, and 88% 
reported having had a colonoscopy since having surgery.  Forty-eight percent 
reported that they had had screening for colorectal cancer before being 
diagnosed (Table 6.1). 
 
Levels of intentions and health beliefs 
Intentions to have a colonoscopy were very high; 96% percent reported 
planning to have a colonoscopy in the next 5 years, and 89% reported that they 
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were extremely likely to have a colonoscopy in the next 5 years.  Seventy-five 
percent of participants reported a desire to have a colonoscopy quite a bit or very 
much.  Because the planning variable did not vary enough, it was not used in 
further analyses. 
On average, participants endorsed benefits of colonoscopy (mean = 4.72), 
suggesting that colonoscopy is viewed as effective in detecting cancers when 
treatment may be more successful (Table 6.2).  Participants did not, on average, 
agree that there are barriers to getting colonoscopy (mean = 1.63).  The cost of 
colonoscopy had the highest level of agreement (mean = 2.10).  Mean levels of 
individual benefit and barrier items are listed in Appendix F. 
Survivors felt their chance of getting colorectal cancer was, on average, 
between slight (2) and moderate (3). However, survivors varied widely in their 
perception of their likelihood of getting colorectal cancer (s.d. = 0.98); 39% felt 
there was a slight chance (2) or no chance (1) of getting colorectal cancer again, 
whereas 28% felt there was a high chance (4) or that they were certain they 
would get colorectal cancer again (5). 
 Participants reported feeling quite confident that they could obtain a 
colonoscopy when they were due (mean self-efficacy = 4.80).  The most 
prevalent cue to action came from participants’ physicians, with 92% of 
participants reporting that at least one doctor recommended routine 
colonoscopies.  48% of participants who had a physician’s recommendation 
reported that a primary care physician recommended a colonoscopy; further, 
87% of participants who had a physician’s recommendation reported that a 
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provider who was not their primary care provider recommended colonoscopy.  In 
addition, 14% of participants got recommendations for colonoscopy from non-
physician healthcare providers, and 23% got recommendations for colonoscopy 
from friends or family.   
 
Primary Hypotheses: Health beliefs and intentions 
In bivariate analyses, most health beliefs were associated with intention to 
have a colonoscopy, as operationalized by desire and expectation to have at 
least one colonoscopy in the next 5 years.  Survivors who had higher perceived 
likelihood (OR = 1.72 for desire and OR=2.54 for expectation, p-values < 0.001), 
greater perceived benefits (OR=2.33, p<0.05 for desire and OR = 2.36 for 
expectations, p < 0.01), and lower perceived barriers (OR=0.35 for desire and 
OR=0.30 for expectation, p-values<0.001) were more likely to have greater 
desire and expectations to undergo colonoscopy.  Having a recommendation 
from a primary care physician was associated with a higher likelihood of greater 
desires (OR=2.05, p<0.05) and expectations (OR=4.30, p<0.01) to have a 
colonoscopy, but recommendations from other healthcare providers or from 
family members and friends had inconsistent relationships with desires and 
expectations.  Self-efficacy was not associated with intentions to have a 
colonoscopy in the future. 
The effect of each of the health beliefs on intentions did not vary by either 
stage of colorectal cancer at diagnosis nor by severity of comorbidities; therefore, 
no interaction terms were included in the multivariable models.  In multivariate 
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analyses (Table 6.3), many of the associations between health beliefs and 
intentions were maintained.  Greater perceived likelihood of getting colorectal 
cancer again was associated with greater intentions to receive a colonoscopy 
(OR = 1.76 for desire and OR = 3.76 for expectation, p-values <0.01).  Those 
with lower perceived barriers had greater desires to receive a colonoscopy (OR = 
0.40, p <0.01), although perceived barriers were unrelated to expectations of 
having a colonoscopy.  Perception of benefits was not associated with intentions.  
Of the cues to action (including getting a recommendation for a colonoscopy from 
a primary care physician, other physician, other health care provider, or family or 
friends), only a recommendation from a primary care physician was associated 
with higher expectations of colonoscopy (OR = 6.53, p< 0.05), and 
recommendations from people who were not healthcare providers were 
associated with less desire to get a colonoscopy (OR = 0.28, p<0.01).   
 
Secondary hypotheses: Health care use and intentions 
In bivariate analyses, having seen a primary care physician in the year 
since diagnosis was associated with stronger desire (OR = 4.41, p<0.05) but not 
with expectations to have colonoscopies in the future.  Those who had a 
colonoscopy after diagnosis were more likely to have greater desires (OR=3.90, 
p <0.001) and expectations (OR=9.54, p<0.001) to have a colonoscopy in the 
future.  Having had screening before diagnosis was not associated with 
intentions. 
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In multivariate analyses, having seen a primary care physician since 
diagnosis and having been screened before diagnosis were each unrelated to 
participants’ surveillance intentions.  Those who had colonoscopy since surgery 
for their disease had greater intentions to have colonoscopy in the future (OR = 
5.72 for desire, p<0.01 and OR = 22.14 for expectation, p<0.05). 
 
6.5  Discussion 
 
Intentions and behavior 
Although colorectal cancer survivors are at increased risk for a second 
primary or a local recurrence,2, 4  they often receive less surveillance than 
recommended.12-18, 44  Because of their history of colorectal cancer, one might 
expect colorectal cancer survivors to hold beliefs that would support surveillance.  
Using a population-based study of patients with newly-diagnosed colorectal 
cancer, we used the HBM to identify potentially modifiable predictors of long-term 
(4-year) colorectal cancer surveillance among colorectal cancer survivors. 
Overall, participants expressed high intentions to receive colonoscopy in 
the next 5 years.  Given that these participants have already been diagnosed 
with, and successfully treated for, colorectal cancer, it is not surprising that they 
would intend to engage in preventive behavior in the future.  However, this high 
level of intention contrasts with the low rates of colonoscopy found in other 
studies.  One possibility is that in this group of participants, surveillance 
colonoscopy rates will be higher than in previous studies. This may be because 
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our sample consists of survivors who have not had a second primary and are 
well enough and motivated to participate in three interviews during a 4-year 
period.     
If this sample ultimately has a low colonoscopy rate despite high 
intentions, other variables may explain this gap between intentions and behavior.  
One such moderator may be perceived barriers to colonoscopy.  Despite a low 
mean barrier score in this study, participants identified barriers that were 
associated with reduced desires to receive colonoscopy and that may also be 
associated with undergoing a colonoscopy.  For instance, cost was the most 
endorsed barrier, and cost may present a stronger barrier to actually getting a 
colonoscopy than simply intending to undergo a colonoscopy.  Similarly, 
concerns about the embarrassment of having a colonoscopy may present more 
of a concern when it is actually time to schedule and receive a colonoscopy.  
Although this effect of perceived barriers on colonoscopy use is speculative, the 
colorectal cancer screening literature shows consistently that barriers are 
associated with colorectal cancer screening behavior in asymptomatic adults.22, 
25, 26, 45  Alternatively, if there is a gap between intentions and actual colonoscopy 
use, participants may have reported strong intentions because this response 
seemed socially desirable. 
 
Association of health beliefs and intentions 
Perceived likelihood of colorectal cancer was an important predictor of 
intentions to undergo colonoscopy.  The few published studies in the area 
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suggest that survivors are concerned about recurrence.  A multi-state survey 
study found that 68% of colorectal cancer survivors 1 year after diagnosis feel 
fearful that their illness will return,46  the top-ranked concern among a list of 29 
concerns.  In another survey study of 96 colorectal cancer survivors who 
responded at variable times after completion of their treatment, 92% of colorectal 
cancer survivors reported believing that they were at risk for recurrence.47   
Although the perceived likelihood of getting colorectal cancer was high in 
this study, there was substantial variation in this measure, suggesting that there 
is room for adjusting these perceptions in order to increase intentions to undergo 
colonoscopy.  Some survivors clearly underestimate their likelihood of getting 
colorectal cancer:  8% reported having no chance of a recurrent colorectal 
cancer, even if they do not get regular colonoscopies.  If perceived likelihood 
drives not just intention but actual surveillance behavior, addressing this 
erroneous perception presents a useful target for intervention.  Survivors must 
understand their risk and perceive it as modifiable through their own actions.48, 49  
A Cochrane review of interventions that use risk communication to help people 
make informed decisions about screening found that tailored risk 
communications had a modest effect on screening behavior.50   
Survivors who perceived greater barriers to getting a colonoscopy 
reported lower desires to have a colonoscopy in the future, whereas perceived 
benefits showed no association with either intention measure.  This suggests that 
interventions targeted to colorectal cancer survivors should focus on reducing 
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barriers (such as cost and transportation) rather than emphasizing the benefits 
that arise from early detection via colonoscopy. 
Cues to action had mixed effects on intentions.  A recommendation from a 
primary care provider was positively associated with expectations to have a 
colonoscopy, but was not associated with desire to have a colonoscopy.  
Physician recommendations have been shown to be related to colonoscopy 
screening.51-53  Surprisingly, receiving a recommendation from someone other 
than a healthcare provider (typically reported as a family member or friend) had a 
negative association with desire to have a colonoscopy, but had no effect on 
expectations.  Perhaps friends and family members were more likely to suggest 
ongoing care to survivors who appeared reluctant to have appropriate 
surveillance in the future.  Similarly, perhaps survivors who had doubts or 
concerns about getting colonoscopies may have asked for advice from friends 
and family members, eliciting recommendations for colonoscopy use.  In both of 
these scenarios, survivors who received recommendations from friends and 
family members may have had less strong intentions to get colonoscopies in the 
future, which could have resulted in a negative association between 
recommendations from those who are not healthcare providers and colonoscopy 
intentions.  The operationalization of cues to action has not been systematically 
studied in the screening literature,19 nor in the surveillance literature, perhaps 
indicating that recommendations may not be appropriate cues.  A more salient 
cue, such as an actual referral to a colonoscopy, may have had a more direct 
effect on intentions.  
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 Other health beliefs that have been shown to predict colorectal cancer 
screening were not significant in our sample of survivors.  These include 
perceived benefits of undergoing colorectal cancer screening23, 26, 45 (although 
effects are mixed22, 25), and self-efficacy.45, 51  Our null results may reflect a 
difference in the role of health beliefs between screening in the general 
population and surveillance among colorectal cancer survivors.  After 
experiencing the diagnosis and treatment of cancer, the benefits to colonoscopy 
may seem obvious, and the task of getting a colonoscopy (after more invasive 
treatments) may not seem insurmountable, causing a ceiling effect in perceived 
benefits and self-efficacy.  Perhaps more sensitive measures need to be created 
to assess these variables among survivors. 
 
Past behaviors and intentions 
The other predictor of greater intentions to get a routine colonoscopy was 
having already had at least one routine colonoscopy since diagnosis.  Because 
this study excluded survivors who were diagnosed with a second primary cancer 
or recurrence, any prior colonoscopy either had normal results or indicated 
precancerous polyps that were presumably removed.  It is therefore not 
surprising that survivors who had both interest in and access to an earlier 
colonoscopy, which yielded either normal results or a reduction in future cancer 
risk, would report an intention to continue with preventive care. 
 
Limitations and conclusions 
   118 
There are several limitations of this paper.  First, because the data are 
cross-sectional, we cannot make causal statements about the association 
between health beliefs and intentions.  Second, intentions may not reflect actual 
behavior, although a meta-analysis of 10 meta-analyses found that intentions 
strongly predict behaviors across studies.54   Additionally, a meta-analysis by 
Webb and Sheeran of 47 experiments manipulating intentions showed that 
changes in intention led to corresponding changes in behavior.55 Finally, this 
study was conducted in a single state, in a highly insured population with very 
high use of primary care, which limits its generalizability.   
 We extended research on cancer behaviors from screening to surveillance 
among a diverse sample of registry-ascertained colorectal cancer survivors.  
Because of their history of cancer, survivors may well evaluate benefits, barriers, 
likelihood of future disease, self-efficacy, and cues to action differently from those 
encouraged to have cancer screening.  Moreover, they are at greater risk than 
the rest of the population for contracting a future colorectal cancer.  The National 
Cancer Institute and other organizations have prioritized research on cancer 
survivorship in order to better assess long-term health services use and 
outcomes.29  We found that survivor’s perceived likelihood of getting colorectal 
cancer again, as well as their perception of barriers to undergoing a colonoscopy, 
are associated with interest in ongoing routine colonoscopies among colorectal 
cancer survivors four years after diagnosis.  It is important to identify drivers of 
colonoscopy utilization and pragmatic interventions that capitalize on these 
findings to facilitate surveillance.  
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Figure 6.1.  Conceptual framework, based on The Health Belief Model 19  
 
Note: CRC = colorectal cancer
Survivor factors: 
• Demographics (age, 
sex, race/ethnicity, 
insurance, income) 
• Clinical 
characteristics (site of 
tumor, stage at 
diagnosis, 
comorbidities) 
• Health services use 
(having seen a primary 
care provider, having 
had screening before 
diagnosis, having had 
colonoscopy after 
diagnosis) 
• Has a primary care 
physician 
Perceived likelihood of CRC: 
• Likelihood of getting CRC again if 
not screened routinely 
 
Intention to 
receive 
colonoscopy 
 
Perceived benefits of 
colonoscopy: 
• Benefits of finding and treating 
CRC early 
•  Effectiveness of colonoscopy at 
finding CRC early, reducing 
mortality, and reducing worry 
 
Perceived barriers to 
colonoscopy: 
• Concerns about inconvenience, 
discomfort, and risks of 
colonsoscopy 
• Cost and transportation problems 
• Belief that colonoscopy is 
unnecessary 
Cues to action: 
• Recommendation from: 
     • primary care physician 
     • non-primary care physician 
     • other healthcare provider 
     • person who is not a healthcare  
        provider 
 
Self-efficacy 
• Confidence in being able to get 
screening when due 
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Figure 6.2.  Flowchart of study participants 
 
Note: NC = North Carolina, CRC = colorectal cancer
736 North Carolina CanCORS CRC participants completed 1-year interview 
316 not yet at 3.5 years from diagnosis 
74 refused, unreachable, incapable 
18 deceased  
13 in treatment 
14 had colectomy 
23 had metastasis or new primary CRC 
 
226 participants in analytic sample 
13 no surgery date 
16 no stage 
8 stage IV 
7 stage 0 
8 did not report intentions 
 
278 completed 4-year interview 
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Table 6.1. Sample characteristics (N = 226) 
Characteristic    % 
Age 65 or older 46 
Income $50,000 or more 47 
Insured  96 
High school or more education 53 
Stage  
I 36 
II 29 
III 35 
Female 53 
White race (vs. nonwhite) 78 
Comorbidities  
None 30 
Mild 43 
Moderate 18 
Severe 9 
Colon cancer (vs. rectal cancer) 80 
Saw a primary care provider in first year 96 
Screening for CRC before diagnosis  48 
Had colonoscopy since diagnosis  88 
Note: CRC = colorectal cancer.  % =  to percentage of nonmissing 
observations. 
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Table 6.2.  Mean values of health beliefs 
Health Belief N Mean (s.d.) 
Perceived likelihood of getting CRC again if you do 
not get regular colonoscopies (1=no chance, 
5=certain to get it) 
202 2.80 (0.98) 
Perceived benefits summary score (1=strongly 
disagree, 5=strongly agree) 
225 4.72 (0.44) 
Perceived barriers summary score (1=strongly 
disagree, 5=strongly agree) 
226 1.63 (0.60) 
Self-efficacy (1= not at all confident, 5= extremely 
confident) 
  
How confident are you that you can get a 
colonoscopy when you are due? 
226 4.80 (0.67) 
 N % 
Cues to action   
Have any of your doctors recommended that you 
have a colonoscopy?   
221 93% 
If yes, were any the primary care provider 221 48% 
If yes, were any NOT the primary care 
provider 
222 87% 
Has any other health care provider ever mentioned 
that you should get regular colonoscopies after 
you get treated for colorectal cancer? 
225 14% 
Has anyone other than a health care provider 
mentioned that you should get regular 
colonoscopies after you get treated for CRC? 
225 23% 
Note: s.d. = standard deviation, CRC = colorectal cancer
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VII. DISCUSSION 
 
Because colorectal cancer survivors are at elevated risk for recurrences and 
second primary colorectal cancers, clinical practice guidelines recommend ongoing 
routine surveillance with colonoscopy.  However, prior studies suggest that some 
colorectal cancer survivors receive too few or no colonoscopies, reducing the 
chance of early detection.  On the other hand, some colorectal cancer survivors 
undergo colonoscopies too frequently, increasing the risks of harm from the 
procedure, false positives, and overwhelming already burdened colonoscopy 
practices.   
Prior studies of overuse and underuse of surveillance colonoscopy among 
colorectal cancer survivors have several limitations.  First, survivor characteristics 
related to colonoscopy use have not been studied in a population-based setting that 
includes uninsured and younger patients.  Second, the determinants of overuse of 
colonoscopy have not been fully explored.  Third, potentially important 
characteristics of survivors have not been addressed in earlier studies.  Finally, prior 
studies have focused on clinical and demographic characteristics that are immutable 
and may not provide insights into potential strategies to increase surveillance 
This dissertation capitalizes on large, multi-regional data on an inception 
cohort of colorectal cancer survivors in order to address these limitations.  
Specifically, I sought to understand the extent of colonoscopy use, identify predictors 
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of both underuse and overuse of colonoscopy, and extend the HBM to understand 
health beliefs underlying colonoscopy use among colorectal cancer survivors.  The 
first two specific aims of this dissertation (papers 1 and 2) focus on the survivor 
characteristics in both the national cohort and NC cohort that predict colonoscopy 
use.  The third specific aim (paper 3) focuses on the role of health beliefs. The 
following discussion will summarize the findings from the dissertation, discuss their 
implications, describe limitations and strengths, and suggest directions for future 
research. 
 
7.1  Findings 
 
Surveillance colonoscopy rates 
We found that there is both underuse and overuse of colonoscopy among 
colorectal cancer survivors.  The first paper found that, according to medical records, 
only 40% of colorectal cancer survivors underwent colonoscopy in the first 14 
months after surgery.  At the time of the study, clinical practice guidelines conflicted 
about whether the first surveillance colonoscopy should occur at 1 year or 3 years 
after surgery, so the low rate of surveillance may not actually reflect underuse and 
should be interpreted with care.  The second paper also found underuse:  only 72% 
of colorectal cancer survivors in North Carolina reported having had a routine 
colonoscopy four years after diagnosis.  The time frame of the first paper’s analysis 
(14 months after surgery) is not perfectly comparable to prior studies of colonoscopy 
underuse, but 40% is somewhat lower than the rates found at 18 months in other 
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studies (52-61%),1-5 and 72% in 4 years is within the range found at 3 years in other 
studies (60-75%),1, 5, 6 suggesting that these estimates are similar to earlier findings.   
The second paper found that 21% of survivors reported having overly 
frequent routine colonoscopies by 4 years after diagnosis, consistent with other 
reports of multiple colonoscopies in short time spans.1, 4, 7 
 
Survivor characteristics 
We failed to identify characteristics of survivors associated with overuse, 
which may be a function of our sample size (see Limitations section below)  Thus, 
this section will focus on underuse.  We found that rates of receipt of surveillance 
colonoscopy varied by clinical and sociodemographic characteristics of survivors, as 
well as by geographic region.  Further, colonoscopy use appears to be correlated 
with use of other health services.  These findings are discussed below. 
Clinical characteristics.  At both 14 months and at 4 years, survivors with 
more severe comorbidities were less likely to have had any colonoscopies than 
survivors with no comorbidities.  It is unknown whether this is because physicians 
are less likely to refer more sick patients, whether more sick patients are less willing 
to undergo this procedure, or both.  Some of the survivors with more severe 
comorbidities may not benefit from colonoscopy use.  Early detection and 
subsequent treatment may not extend survival or improve quality of life for these 
survivors.  If this is the case, “underuse” may be an inappropriate descriptor of a 
situation in which survivors are appropriately receiving less surveillance.  Evidence 
regarding the benefit of colonoscopy for very old and very sick survivors should be 
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evaluated to determine whether sicker survivors are underserved or being 
appropriately tested. 
Although guidelines for colonoscopy are identical for survivors of colon and 
rectal cancer, those with rectal cancer were less likely to have undergone 
colonoscopy by 14 months than those with colon cancer.  Current surveillance 
guidelines recommend supplemental sigmoidoscopies for rectal cancer survivors.  
Although surveillance sigmoidoscopy use was not assessed in our medical record 
review, prior research shows that survivors do not substitute sigmoidoscopy for 
coloscopy.8  After 4 years, patterns of underuse and overuse of surveillance 
colonoscopies was similar for both tumor sites.  It is unknown whether this 
discrepancy between colon and rectal cancer survivors disappears by 4 years, or 
whether the analysis in paper 2 was underpowered to find a difference.  Further 
research should look into whether rectal and colon cancer survivors differ in 
important ways that contribute differently to appropriate surveillance in colorectal 
cancer survivors. 
Sociodemographic characteristics.  Unlike findings from previous studies, this 
dissertation demonstrated minimal influence of sociodemographic factors on 
colonoscopy use.  In paper 1, survivors who were neither black, white, nor Hispanic 
were more likely to undergo a colonoscopy; however, the group was both too small 
and too heterogeneous to fully understand this effect.  In both papers 1 and 2, age, 
sex, marital status, and education were unrelated to survivors receipt of 
colonoscopy.  The effect of age has been seen in some prior studies with very old 
survivors (over 85 years);3, 6, 9 however, we had too few survivors in this age group 
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(7% and 1%, respectively, in the national and North Carolina cohorts) to examine the 
effect of very old age on colonoscopy use.  Similarly, despite the national, diverse 
population sampled for CanCORS, 98% of survivors in the medical record study and 
95% of survivors in the self-report study were insured, making the effect of insurance 
impossible to determine.  Income, which may serve as an imperfect proxy of 
insurance, was not associated with colonoscopy use in either study.  Because 
access to care may be an important variable in determining whether survivors 
receive appropriate surveillance, it is surprising that income is unrelated to 
colonoscopy use.    
Health care use.  In the national cohort, survivors who visited a primary care 
provider in the first year after diagnosis were more likely to have a colonoscopy in 14 
months after surgery.  Whether this is because primary care providers directly 
referred survivors to colonoscopy or whether survivors who see primary care 
providers are also likely to have access to, and/or interest in, preventive care and 
services is not known.  No prior studies have investigated referral patterns for 
colonoscopies among survivors, and whether primary care physicians refer survivors 
often.  Survivors in the NC cohort (paper 2) provided some insight into referral 
patterns; those whose physicians recommended colonoscopies reported the 
physicians’ specialties.  The largest subset (30%) was general practitioners or 
internists, who are the most likely to be primary care providers.  The next most 
common specialty recommending colonoscopy was gastroenterologists (26%), 
followed by oncologists (21%).  Confirming these self-reported assessments with 
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medical records or administrative data is an important step in understanding 
variations in colonoscopy use and resolving disparities. 
Medical oncology visits and adjuvant chemotherapy use were also related to 
colonoscopy use in the national cohort (paper 1).  Like primary care visits, these 
could be indicators of access to preventive care.  Visits to medical oncologists, 
adjuvant chemotherapy use, visits to primary care physicians, and surveillance 
colonoscopy use may all result from both access to and interest in ongoing 
preventive care. 
 Regional variation.  In the national cohort, colonoscopy use varied by region.  
Survivors in Northern California were less likely to undergo colonoscopy by 14 
months than those in other regions, and there was an almost three-fold difference in 
colonoscopy rates across study centers.  Because study centers were either 
population-based, a group of VA hospitals, or a group of managed care 
organizations, it is impossible to know whether these regional differences reflect 
differences in health systems.  However, geographic variations in colonoscopy use 
have been seen before in studies of colorectal cancer survivors using SEER-
Medicare data.7, 9  Practice patterns may vary by geographic region.  Regardless of 
the reason, this variation is troubling.  Clinical practice guidelines are intended to 
promote a standard for evidence-based care.  Despite the presence of guidelines, 
wide regional variation remains in the care of colorectal cancer survivors.   
 
Intentions 
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 Aim 3 examined intentions to have colonoscopy in the next 5 years, an 
interval during which every survivor would be due for at least one routine 
colonoscopy.  Intentions are important because they are likely necessary, albeit not 
sufficient, for patients to engage in health behaviors, such as cancer screening and 
surveillance.  We conceptualized intentions in three different ways:  planning, 
expecting, and desiring to have at least one colonoscopy in the next 5 years.  
Intentions in all 3 conceptualizations were very high among the NC cohort.  This is 
not surprising:  as 4-year survivors of colorectal cancer, they were likely to hold 
attitudes that support surveillance to prevent second primary colorectal cancers and 
recurrences.   
 Whether survivors who intend to undergo surveillance actually receive 
colonoscopy is unclear.  Intentions are not perfect predictors of behavior.10  In his 
review of the relationship between intentions and behavior, Sheeran listed several 
factors related to whether intentions can be enacted as behaviors: knowledge of the 
behavior; ability, resources, and opportunity to perform the behavior; availability of 
the resources needed to perform the behavior; cooperation by anyone else involved; 
and ability to perform the behavior if unexpected situations arise.10  Some of these 
factors are relevant to colonoscopy, such as needing resources (money, 
transportation) and cooperation (another person to bring the patient to the 
appointment and back) in order to translate intention into behavior.  It is possible that 
despite strong expectations and desires to have colonoscopies, any of these factors 
may affect whether survivors actually undergo colonoscopies.  Indeed about a fifth of 
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the NC cohort reported past underuse of colonoscopy despite expressing strong 
intentions to undergo colonoscopy in the future.    
 
Predictors of intentions: past health behaviors 
 Past behavior is often a good predictor of future behavior,10 and for 
surveillance colonoscopy, having had a routine colonoscopy since diagnosis 
indicates both access to colonoscopy and enough interest to follow through with the 
procedure.  However, when comparing survivors who had and had not received 
colonoscopy since their colorectal cancer diagnosis, we found no differences in 
desire or expectation to have another colonoscopy within the next 5 years.  Perhaps 
survivors who have had at least one colonoscopy since surgery do have greater 
intentions to have future colonoscopies, but they do not know that they are due for 
another colonoscopy within 5 years. The schedule for surveillance has shorter 
intervals than the schedule for screening, with which they may be more familiar.  
Alternatively, perhaps survivors who have already undergone surveillance since 
surgery found the experience unpleasant enough that they genuinely have no 
greater surveillance intentions than those who have not undergone surveillance 
since surgery. 
 Similarly, having seen a primary care provider had no relationship with either 
desires or expectations to have at least 1 colonoscopy in the next 5 years.  Although 
visiting a primary care provider indicates that the survivor is getting some degree of 
ongoing care, these visits did not correlate with intentions to undergo colonoscopies.   
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 As hypothesized, survivors who had screening before diagnosis were more 
likely to have greater expectation of having a colonoscopy and greater desire to 
have a colonoscopy than those who did not get screening.  Those who had 
screening had had both interest in and access to prevention in the past, which may 
have influenced their attitudes toward prevention in the future. 
 Having seen a primary care provider had no relationship with either desires or 
expectations to have at least 1 colonoscopy in the next 5 years.   
 
Health beliefs as predictors of intentions 
 As hypothesized, health beliefs were related to colonoscopy intentions.  
Specifically:   
• Perceived likelihood of colorectal cancer.  Survivors who felt they were more 
likely to get colorectal cancer had greater intentions to have a colonoscopy in 5 
years.   
• Perceived benefits and barriers.  Survivors generally felt that colonoscopy is 
beneficial in reducing the threat of colorectal cancer, and they perceived minimal 
barriers to getting routine colonoscopy.  Although the perception of greater 
benefits of colonoscopy was unrelated to intentions to undergo routine 
surveillance, survivors who perceived lower barriers to undergoing colonoscopy 
were more likely to strongly desire a colonoscopy.  There was no association of 
barriers and expectations.   
• Self-efficacy.  Self-efficacy, which has been shown to be related to intention to 
have colorectal cancer screening in one study,11 was very high in the NC cohort, 
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with too little variation to be included as a predictor to model intentions.  
Therefore, a more sensitive measure of self-efficacy, such as a measure of 
confidence in the particular actions involved in getting a colonoscopy (e.g., 
preparation, transportation, and financing) may be more useful in future studies 
of colorectal cancer survivors. 
• Cues to action.  Cues to action were measured as recommendations by five 
types of individuals: primary care physicians, physicians who were not 
responsible for primary care, other health care providers, and people who were 
not healthcare providers (such as friends and family).  Ninety-three percent of 
survivors had received recommendations from at least one physician to have a 
surveillance colonoscopy.  Physician recommendations have been shown to be 
associated with past use of colorectal cancer screening.11-13  Forty-eight percent 
of survivors received recommendations from primary care physicians, 86% from 
other doctors, 14% from other healthcare providers, and 23% from those who are 
not healthcare providers.  Only recommendations from primary care providers 
were positively associated with expectations of getting a colonoscopy in the 
future.  Recommendations from those who do not provide health care had a 
negative effect on desire to have a colonoscopy, suggesting that friends and 
family members were more likely to encourage colonoscopy use if survivors were 
reluctant to undergo surveillance, or that survivors who were conflicted may have 
sought advice from friends or family members. 
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 These findings underscore that clinical and sociodemographic factors do not 
fully describe the pattern of colonoscopy use among colorectal cancer survivors.  
Individual health beliefs affect colonoscopy intentions and may affect colonoscopy 
use as well.  Further, these beliefs are potentially modifiable in order to better align 
colonoscopy use with guidelines.   
 
Comparison of predictors across studies 
 Although all three papers investigated predictors of similar colonoscopy-
related outcomes, the predictors are not identical across studies.  Many of the 
significant predictors of behavior in paper 1 (e.g., site of tumor, stage of disease, 
race) were not significant in paper 2.  Also, sociodemographic and clinical predictors 
of intentions were not reported in paper 3, but older and wealthier survivors were 
more likely to have stronger desires to have a colonoscopy (OR = 1.03 and OR = 
1.15, respectively, p-values < 0.05), and wealthier survivors were more likely to have 
greater expectations of having a colonoscopy (OR = 1.46, p<0.05).  (Appendix G)  
These predictors are different than those found for both of the preceding papers. 
 There are several possibilities for these discrepancies across studies.  First, 
paper 2 may not have been appropriately powered to detect differences in 
colonoscopy use by the variables found to predict colonoscopy use in paper 1.  It is 
possible that with a larger sample size, findings from paper 2 may confirm the 
findings in paper 1.  Second, there may be genuine difference in who undergoes a 
colonoscopy by 14 months as compared to 4 years.  For instance, rectal cancer 
survivors may simply get their first colonoscopy slightly later than colon cancer 
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survivors, and differences between the behavior of the two groups disappears by 4 
years.  Third, paper 2 was limited to North Carolina CanCORS participants.  When 
the analysis from paper 1 was restricted to participants from North Carolina, none of 
the predictors that were significant in the main paper 1 analysis were significant.  
This could be due to limited sample size in the restricted sample (N=416), 
suggesting that paper 2 was underpowered as well, but it could also mean that 
predictors of colonoscopy use are different in North Carolina than they are for all 
CanCORS sites together.   
 Differences in predictors between paper 3 and the other papers could reflect 
differences between the dependent variables in the studies.  Clinical and 
sociodemographic predictors of intentions may differ from clinical and 
sociodemographic predictors of actual behavior.  If these predictors reflect, in part, 
access to care, it makes sense that they have a stronger effect on actual behavior 
than intentions to undergo a colonoscopy.  Alternatively, the inclusion of health 
beliefs as predictors of intentions could have contributed to there being a different 
set of significant predictors than in models that do not take health beliefs into 
account. 
 
Health belief model extended to survivors 
 Extending the HBM to survivors of colorectal cancer sheds some light on 
cognitive factors that influence screening and those that influence surveillance 
colonoscopy.  As a whole, health beliefs were associated with intentions to have a 
colonoscopy, just as they are with screening colonoscopy, suggesting that the HBM 
  141 
is a relevant framework for understanding prevention in both contexts.  Perceived 
likelihood of colorectal cancer and perceived barriers to colonoscopy are related to 
both surveillance colonoscopy intentions and screening behavior.  Both perceived 
likelihood and perceived barriers have been addressed in screening colonoscopy 
interventions and, if further research confirms this study’s findings, both could be 
targeted in interventions to increase colonoscopy use among survivors. 
 
Choice of analytic method 
For paper 1, I  opted for a logistic regression analysis instead of a time-to-
event analysis to determine whether participants underwent at least one 
colonoscopy in the first 14 months after surgery.  Although a time-to-event analysis 
would reduces bias from censoring and would use all of the available data, it would 
answer a different question than that answered by logistic regression.  Specifically, 
rather than establishing predictors of whether survivors had colonoscopy, a time-to-
event analysis would establish predictors of getting an earlier or later colonoscopy.  
Because a later colonoscopy within the limited analysis time available (for example, 
a colonoscopy at 14 months instead of 12 months) does not necessarily indicate 
less appropriate care, and because an earlier colonoscopy (for example, a 
colonoscopy at 10 months instead of 12 months) does not necessarily indicate better 
care, I opted against a time-to-event analysis in favor of logistic regression for the 
dissertation.  A visual inspection of the timing of colonoscopies after surgery 
(Appendix H) confirms that most colonoscopies fell within the later end of the 
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analysis period, suggesting that a further investigation into the timing of 
colonoscopies within 14 months after surgery would not be useful. 
  
7.2  Implications 
 Taken together, these three studies present a more complete understanding 
of factors relating to whether colorectal survivors undergo colonoscopy for 
surveillance.  Specifically, access to ongoing preventive care may be critical in 
helping ensure that survivors receive appropriately timed colonoscopies.  Further, 
survivors with more severe comorbidities are particularly likely to underuse 
colonoscopies.  In addition, survivors’ perceived likelihood about getting colorectal 
cancer again and the perceived benefit of colonoscopy to prevent colorectal cancer 
were related to intentions for subsequent surveillance.  Below, I describe how 
findings from these studies can inform practical changes to be implemented by 
providers, healthcare systems, and policymakers 
 Providers.  Health care providers must either refer survivors for, or actually 
perform, colonoscopies.  However, they must also communicate with and educate 
survivors regarding appropriate use of colonoscopy.  Because survivors generally 
agreed that colonoscopy is beneficial, physicians may do well to emphasize that: 1)  
survivors are at risk for recurrences or second primary colorectal cancers and 2) 
identifying precancerous polyps before they are symptomatic can increase treatment 
options and increase survival.  
Beyond simply conveying facts about colorectal cancer risk, providers may 
consider incorporating interventions to adjust perc
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cancer into their practices.  Extensive research on how to adjust perceptions of 
likelihood of disease in order to increase screening may be adapted to populations 
of survivors.  A Cochrane Collaboration systematic review of 22 studies found that 
personalizing risk information in educational interventions led to an increase in 
screening uptake.14  Similarly, a review by Vernon (1999) found that persuasive 
educational messages were successful in changing perceptions of likelihood of 
getting cancer, although sometimes these interventions had no effect on actual 
screening behavior.15  Providers may want to integrate tested risk communication 
tools into their practice. 
 Providers can also communicate with survivors about their barriers to getting 
colonoscopies so they can use available resources to overcome barriers.  For 
instance, if a healthcare provider learns that transportation is a problem, he or she 
can provide information about agencies that provide transportation.  Similarly, they 
can offer strategies to overcome embarrassment or fear that may keep survivors 
from undergoing recommended colonoscopies.  
Health systems.  Hospitals and health care systems create structures that 
may be able to help providers improve surveillance colonoscopy use among 
colorectal cancer survivors.  One potential strategy is to identify, and provide 
incentives for, quality indicators related to survivorship care.  One quality indicator 
could be discussions about ongoing preventive care for providers caring for all 
cancer patients.  Such discussions should emphasize the importance of having 
ongoing primary care visits and identify any barriers to care, which ideally would 
facilitate the survivor getting not only colonoscopies but other preventive services, 
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such as vaccines, mammography for women, and other routine care.  Healthcare 
systems may want to pay particular attention to the treatment of rectal cancer 
survivors, who have been found to get fewer colonoscopies than colon cancer 
survivors.   
Another quality indicator for healthcare systems could be the provision of a 
survivorship care plan for each cancer survivor. Survivorship care plans have been 
proposed by the Institute of Medicine and endorsed by cancer researchers as a 
more concrete intervention to improve the transition from acute cancer care to 
survivorship care.16-21  A survivorship care plan is a document that oncologists or 
other physicians caring for cancer patients provide to each patient that describes 1) 
his or her diagnosis, 2) a summary of treatment, 3) recommendations for future care 
(such as ongoing colonoscopies), and 4) resources for cancer survivors.19  Research 
has not yet determined how many institutions consistently use survivorship care 
plans, but because the concept is a recent development (2006), the plans are likely 
not in widespread use.   
The above quality indicators are appropriate for sites of cancer care, but other 
indicators may be useful in healthcare systems where survivors get ongoing care in 
order to promote colorectal cancer surveillance.  In this context, quality indicators 
could include whether physicians refer survivors for colonoscopies, or conduct 
colonoscopies, at the recommended intervals.   
Healthcare systems can use various strategies to ensure that such quality 
indicators are prioritized.  Charts of colorectal cancer patients can be flagged at sites 
of cancer care to remind providers to discuss ongoing colonoscopies and identify 
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any barriers to care before the patient completes cancer treatment and may not 
return for later care.  Further, survivorship care plans can be automatically 
generated for each cancer patient.  Similarly, in sites of ongoing care, colorectal 
cancer survivors’ charts can be flagged to remind providers that routine surveillance 
colonoscopies are recommended.  A review of reminder systems found that 
reminder systems, either computer-based or paper-based in charts, have been 
shown to increase preventive care use by 12-14%.22  Finally, healthcare systems 
can link quality indicators to physician evaluations or to their  earnings in a pay-for-
performance system. 
Policy.  Cost was identified as one of the most strongly endorsed barriers to 
colorectal cancer surveillance among survivors.  A concrete step would be to expand 
coverage of surveillance colonoscopy.  According to the Centers for Disease Control 
and Prevention (CDC), the current cost of a colonoscopy is $800 - $1600, which 
may be prohibitive for survivors without insurance.23  Under Medicare Part B, 
colorectal cancer survivors are eligible for a colonoscopy every 2 years, for which 
survivors pay 20%.24  The out-of-pocket cost of $160 - $320 may still be prohibitive 
for some survivors.  The CDC provides free and low-cost mammograms and Pap 
tests for low income women;25 an analogous program providing free and low-cost 
colonoscopies could greatly increase colonoscopy use for colorectal cancer 
survivors. 
 
7.3  Limitations 
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 The limitations of this study have been addressed in more detail in the 
separate manuscripts; however, I will describe some of the major categories.  First, 
the ascertainment of colonoscopy use was limited in both the national and North 
Carolina cohorts.  We measured colonoscopy use using medical records in the 
national cohort.  Study centers may have had different levels of success obtaining 
records from primary care physicians and gastroenterologists, which would bias a 
major dependent variable.  Although a central CanCORS team checked many 
aspects of the medical record data for quality, colonoscopy use was not evaluated.  
Thus, interpretation of colonoscopy rates and differences by region should be 
cautious until confirmed by other studies.  A parallel limitation in colonoscopy 
ascertainment is the measure of colonoscopy by self-report in the North Carolina 
cohort.  Remembering and reporting colonoscopy use over the past 4 years is not as 
accurate as objective medical records or administrative claims.  This may have led 
to participants to remember too many or too few colonoscopies. 
 A second limitation in the national cohort is related to the time frame of the 
analysis.  During the study period, multiple guidelines conflicted about the timing of 
surveillance colonoscopies, with some guidelines recommending a first colonoscopy 
as late as 3 years after surgery.  For this reason, data from the national cohort could 
not assess adherence to guidelines, as it was limited to 15 months of data after 
diagnosis.  Further, in order for the data to include 14 months of follow-up time after 
surgery, survivors who had surgery more than one month after diagnosis were 
censored.  This censoring excluded some survivors who received neoadjuvant 
therapy.  It may be that as with adjuvant therapy, those who underwent neoadjuvant 
  147 
therapy were more likely to undergo colonoscopies, suggesting that our count of 
colonoscopies may be low.  In addition, survivors of rectal cancer are more likely to 
undergo neoadjuvant therapy, and if neoadjuvant therapy use is linked to 
colonoscopy use, excluding a disproportionate number of rectal cancer survivors 
may have artificially widened the gap in colonoscopy use between rectal and colon 
cancer survivors. 
 Third, our study on self-reported behavior (paper 2) was restricted to the 
North Carolina cohort and thus may have been limited by the size of the sample.  
Although the study was powered for an N of at least 100, according to a priori 
calculations, the individual efffect sizes and standard errors suggest the study was 
underpowered.  Post hoc analyses demonstrated that if the estimates found in paper 
2 accurately reflected population means, the sample size would have had to have 
been approximately 3 times larger to detect the effects of sociodemographic 
variables on underuse of colonoscopy.  To detect the same effects on overuse, the 
sample size would require over 100,000 survivors.  For overuse especially, sample 
size clearly could have prevented precise estimation of associations.  However, it is 
also possible that the predictors selected for that analysis simply were unrelated to 
overuse of colonoscopy, which may require an entirely different conceptual model. 
   Fourth, there was limited variation in intentions and some independent 
variables.  The intention measure was skewed toward a strong interest in 
colonoscopy.  Self-efficacy was high among all participants, and other health beliefs 
(such as perceived benefits and perceived barriers) did not vary much.  Future 
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studies of health beliefs and intentions among survivors may need to adapt 
measures to capture differences better and avoid ceiling and floor effects. 
 Finally, the cross-sectional nature of the analyses does not allow estimation 
of causality.  One problem with cross-sectional analyses is that participants simply 
could have reported intentions that were consistent with the health beliefs reported 
earlier.  Also, causality could be reversed from the expected direction, in that having 
strong intentions to have a behavior could then increase one’s self efficacy, reduce 
perceived likelihood of disease, or affect other health beliefs.26  The results of this 
analysis should be interpreted with caution and used as a starting point for future 
longitudinal studies that assess predictors before assessing actual use of 
surveillance colonoscopy. 
  
7.4  Strengths 
 
 This study of colonoscopy use and intentions had many strengths.  Both 
cohorts used recent data, allowing the investigation of more recent trends in 
colonoscopy use than was possible in prior studies.  Both cohorts had rich data from 
an inception cohort of colorectal cancer survivors followed over time.  The national 
cohort took advantage of medical record data over 15 months after diagnosis, which 
included quality-controlled data from multiple providers on diagnosis, staging, and 
ongoing treatment.  The data came from multiple populations across the United 
States and represent a diverse group of survivors.  The NC cohort was registry-
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based and used both medical record data and well-validated, theory-informed survey 
measures to assess colonoscopy use and intentions.   
 
7.5  Future research 
 
Data from CanCORS can be further explored to expand upon the findings 
from this dissertation.  Specifically, decomposing the comorbidity rating into its 
component parts would allow a closer investigation of whether the specific comorbid 
conditions that are linked to less frequent colonoscopy use are serious enough to 
indicate that surveillance colonoscopy would not be beneficial or, alternatively, that 
surveillance colonoscopy is warranted.  If colonoscopy is warranted for certain 
conditions, and survivors with these conditions are less likely to undergo 
colonoscopies, it would suggest that survivors with these comorbid conditions are 
underserved. 
Some findings from this dissertation cannot be explored with CanCORS data 
but should be investigated in future research, such as the variation found between 
study centers found in paper 1.  With additional data that can distinguish between 
health systems and geographic regions, we may better understand the nature of the 
differences found in the dissertation.  For example, if data exist to investigate 
colonoscopy use in managed care systems, VA hospitals, and other non-managed 
care and non-VA systems in Northern California, one could distinguish how health 
care systems and geographic region are differently associated with colonoscopy 
use. 
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There are several directions for research that can build on the findings of this 
study.  First, survivors with greater comorbidity are less likely to receive 
colonoscopy.  Physicians may not recommend surveillance for these survivors if 
they feel that the harms outweigh the benefits.  However, surveillance guidelines for 
colorectal cancer do not account for patient morbidity.  Without accounting for 
morbidity, it may appear that survivors are not receiving appropriate care.  Cost-
benefit analyses may help assess whether frail survivors should receive 
colonoscopies, and the results of these analyses may be useful when updating 
current recommendations.  Indeed, Braithwaite et al. (2007) recently developed a 
framework for calculating the benefit of colorectal cancer screening with 
colonoscopy and suggested such a framework be added to clinical guidelines for 
screening. 27  This approach can be applied to surveillance as well.   
Second, our rates of underuse and overuse by 4 years came from self report, 
the accuracy of which depends on survivors’ ability to recall their colonoscopies.  A 
more accurate estimate of underuse and overuse over the longer term could be 
determined from assessing colonoscopy use in medical records, as was done in 
CanCORS.  However, CanCORS medical records were limited to 15 months after 
diagnosis.  A future study of colonoscopy use among colorectal cancer survivors 
could use medical record data over at least 5 years from diagnosis.  This would 
allow a more accurate assessment of both underuse and overuse under the current 
colonoscopy guidelines.  Such a study would be best performed in an integrated 
system of care, such as the Veterans Affairs health care system or Kaiser 
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Permanente, where records for both cancer care and ongoing preventive care would 
be accessible.  
Third, our study of health beliefs was cross-sectional, limiting our 
understanding of how health beliefs are connected with surveillance colonoscopy.  A 
longitudinal study of health beliefs would better assess how health beliefs are 
associated with later colonoscopy use.   This cohort study could be performed in a 
single institution, combining surveys assessing health beliefs and medical records.  
Findings from a longitudinal study of health beliefs would be more valid than a cross-
sectional survey and would form reasonable bases for intervention.  A necessary 
step in this process is the adaptation and validation of scales to measure health 
beliefs regarding colonoscopy among colorectal cancer survivors.  Scales used in 
this dissertation are a good start, but reliable and useful scales may need to be more 
sensitive to avoid ceiling and floor effects. 
Fourth, the findings from the study of health beliefs and intentions did identify 
perceived likelihood of colorectal cancer as a predictor of intentions to undergo 
surveillance colonoscopy, which presents a useful target for intervention.  An earlier 
recommendation in this discussion suggested that physicians integrate risk 
communication tools into their practices, in order to adjust colorectal cancer 
survivors’ perception of their likelihood of getting colorectal cancer in the future.  
Risk communication tools have been developed for colorectal cancer screening,14 
but none have been developed for colorectal cancer surveillance among survivors.  
Future research should 1) adapt risk communication methods from successful 
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colorectal cancer screening interventions and 2) evaluate the effectiveness of such 
an intervention directed at colorectal cancer survivors. 
Finally, survivorship care plans have been put forth by the American Society 
of Clinical Oncology28 and the Institute of Medicine,19 and a plan has been 
developed specifically for breast cancer survivors.16  Some cancer centers, such as 
the Fred Hutchinson Cancer Center,29 Memorial Sloan-Kettering Cancer Center30, 
have such plans as well, and one is being developed for the University of North 
Carolina’s Lineberger Comprehensive Cancer Center.31  Although they share some 
features, there is no standard format for these plans, and their effectiveness has not 
been tested.  Because these plans are intended to be provided to survivors to share 
with their primary care physicians, such plans should be evaluated to ensure that 
important information about diagnosis, ongoing risks, and recommendations are 
understood by both survivors and physicians.  The goal of such an evaluation study 
would be to develop an appropriate set of components that are presented optimally 
for both providers and survivors. 
Further, although survivorship care plans appear to be a useful intervention, 
the effectiveness of survivorship care plans is purely speculative at this point.  A trial 
of a survivorship care plan should be implemented to understand the effect of such 
plans on use of primary care, receipt of preventive services (such as colonoscopies), 
and, if the trial can follow survivors for several years, outcomes of care. 
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7.6  Summary 
 
The dissertation addressed important questions about the use of surveillance 
colonoscopy among colorectal cancer survivors.  The dissertation found that in 2 
diverse cohorts of colorectal cancer survivors, colonoscopy is underused by some 
survivors and used too frequently by others.  The studies in this dissertation 
identified rectal cancer survivors as particularly vulnerable to underuse of care.  
Survivors with severe comorbidities were less likely to undergo colonoscopies as 
well, although this less frequent use may have been appropriate.  Primary care use 
was found to be correlated with colonoscopy use, suggesting that continuity of care 
should be further explored in understanding colonoscopy use by colorectal cancer 
survivors.  In addition, survivors who felt they had a higher chance of getting 
colorectal cancer had greater intentions to undergo colonoscopy in the future, 
whereas survivors who perceived greater barriers to obtaining a colonoscopy had 
lower intentions to undergo colonoscopy in the future.  Findings from these studies 
can inform strategies for physicians, healthcare systems, and policy makers to 
improve adherence to colonoscopy guidelines for colorectal cancer survivors.   
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APPENDIX A. Screening sheet and questionnaire 
 
 
 
Study ID ________________________________  Date __________________ 
 
Is patient finished with treatment?   (any chemotherapy counts) 
 
 YES   Continue NO   Stop 
 
Has patient had total colectomy (all of colon is removed)? 
 
 YES   Stop NO   Continue 
 
Local recurrence of colorectal cancer? 
 
 YES   Stop NO   Continue 
 
New primary colorectal cancer? 
 
 YES   Stop NO   Continue 
 
Has patient had metastasis anywhere? 
 
 YES   Stop NO   Continue 
 
QA.  Reason for not doing interview [If can’t decide most important, choose highest 
up on list]: 
Not finished with treatment.........................................1 
Had total colectomy....................................................2 
Had local recurrence ..................................................3 
Had a new primary colon cancer................................4 
Had metastasis ........................................................12 
Hard of hearing ..........................................................5 
Cognitive deficits / language problems / 
low functional literacy............................................6 
Respondent / interviewer was out of time...................7 
Fatigue / not feeling well.............................................8 
Emotional ...................................................................9 
Logistical (e.g., phone problems) .............................10 
Other (write in Notes field)........................................11 
 
  158 
The next questions are about the time after you completed treatment for your 
colorectal cancer.   
 
 1. Do you have a primary care doctor? 
 
[If needed, prompt: Some people have a primary care doctor. This doctor may be 
your family doctor, a general doctor, or a specialist doctor. Sometimes your 
primary care doctor is someone who has known you for many years and 
sometimes it may be a doctor that your insurance company or health plan 
assigns to you who may not know you very well. This is usually somebody 
outside of your oncology practice. ] 
 
YES............................1   
What is his or her specialty? _________________  
 
If not known, name: _________________________________ 
NO .............................2  [GO TO 3]  
DON’T KNOW............8 [GO TO 3] 
REFUSED................. 9  [GO TO 3] 
 
2.Since you finished treatment for your colorectal cancer, have you seen your 
primary care provider?  
 
YES............................1 
NO .............................2  
DON’T KNOW............8 
REFUSED..................9  
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 3. The next questions are about two types of medical tests of your colon that 
you may have had since you were diagnosed with colorectal cancer.   
 
Since you had surgery for your colorectal cancer, have you had a colonoscopy?  
 
[If needed, prompt: A colonoscopy is a test that must be conducted either in a 
hospital or doctor’s office.  A lighted tube is inserted into the rectum and used 
view the entire colon. You are usually given medicine through a needle in your 
arm to make you sleepy for this test, and you need someone to drive you home 
afterwards.] 
 
YES........................... 1 
NO ............................ 2   [GO TO 6] 
3A.  Have you ever been told that you should not have a colonoscopy for any 
reason? 
[If NO, GO TO 6] 
[If yes]  What is the reason? ___________________Stop survey 
DON’T KNOW............8  [GO TO 6] 
REFUSED................. 9   [GO TO 6] 
 
 4. How many colonoscopies have you had since you had surgery for your 
colorectal cancer?  
 
NUMBER _____ 
 
 5. Please tell me when you had these colonoscopies, starting with the most 
recent one. 
Colonoscopy Date 
(Enter date or # from list below if they 
need prompt) 
Reason for Colonoscopy 
(Enter # from below, and write in other 
reasons if needed) 
 _____/_____              ________ 
    month              year              or # below 
_____________________ 
  _____/_____              ________ 
    month              year              or # below 
_____________________ 
_____/_____              ________ 
    month              year              or # below 
______________________ 
_____/_____              ________ 
    month              year              or # below 
______________________ 
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If they can’t remember, prompt:  
 
Within a year after surgery .................1 
More than 3 years ago, but after 
surgery...2 
Between 2 and 3 years ago .................3 
Between 1 and 2 years ago ……..…...4 
Less than 1 year ago  ……………...5 
OTHER (write in above)  ..................6 
DON’T KNOW ..................................8 
REFUSED ……………………....…9 
If they can’t remember, prompt:  
 
PART OF A ROUTINE EXAM OR 
CHECKUP ..1 
BECAUSE OF A SYMPTOM ….…….2 
FOLLOW-UP OF AN EARLIER 
ABNORMAL TEST ……………..…...3 
OTHER (write in above) ...........................4 
NOT SURE .........................…………..…8 
REFUSED ……………………………..9 
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 6. Since you had surgery for your colorectal cancer, have you had a 
sigmoidoscopy?  
 
[If needed, prompt: A sigmoidoscopy is a test that must be conducted either in a 
hospital or doctors office.  A lighted tube is inserted into the rectum and used to 
view the lower part of the colon, and you are able to drive yourself home 
afterwards.  You are not given anything to make you sleepy for this test.  ] 
 
YES............................1 
NO .............................2   [GO TO 9] 
DON’T KNOW............8  [GO TO 9] 
REFUSED................. 9   [GO TO 9] 
 
 7. How many sigmoidoscopies have you had since you had surgery for your 
colorectal cancer?  
NUMBER _____ 
 
 8. Please tell me when you had these sigmoidoscopies, starting with the most 
recent one. 
 
Sigmoidoscopy Date 
(Enter date or # from list below if they 
need prompt) 
Reason for Sigmoidoscopy 
(Enter # from list below, and write in other reasons 
if needed) 
 ____/___          _________ 
  month    year         or # below 
 
 ____/___          _________ 
  month    year         or # below 
 
 ____/___          _________ 
  month    year         or # below 
 
 ____/___          _________ 
  month    year         or # below 
 
 
If they can’t remember, prompt:  
 
Within a year after surgery ........1 
More than 3 years ago, but after 
surgery..2 
Between 2 and 3 years ago ........3 
Between 1 and 2 years ago .…..4 
Less than 1 year ago …………..5 
OTHER (write in above) .............6 
DON’T KNOW …………......…8 
REFUSED……....................…..9 
 
 
If they can’t remember, prompt:  
 
PART OF A ROUTINE EXAM OR 
CHECKUP ..1 
BECAUSE OF A SYMPTOM  ……….….2 
FOLLOW-UP OF AN EARLIER 
ABNORMAL TEST ……………………...3 
OTHER (write in above) ...........................4 
NOT SURE ……….................…………..8 
  REFUSED ……………………………..…9 
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 9. Sometimes people without colorectal cancer have screening for colorectal 
cancer.  This means having a test for colorectal cancer even when there are no 
symptoms.  These tests can be colonoscopy, sigmoidoscopy, fecal occult blood 
test (or FOBT), or barium enema.  Did you have any screening tests before you 
were diagnosed with colorectal cancer? 
 
YES.....................................................1 
NO ......................................................2    
DON’T KNOW.....................................8   
REFUSED.......................................... 9    
 
10. Some doctors recommend that people who have had colorectal cancer 
should get colonoscopies regularly to detect cancer in the colon or rectum.  My 
next questions are about your plans to have colonoscopies in the future. 
 
 [If respondent asks about what the regular interval is, state that it depends on 
your doctor, and they should ask their doctor what they think is the best timing for 
colonoscopies.] 
 
How much do you want to have a colonoscopy in the next five years? 
 
Want to very much..............................1 
Quite a bit ...........................................2 
Somewhat...........................................3 
A little bit .............................................4  
Not at all..............................................5 
DON’T KNOW.....................................8 
REFUSED...........................................9  
 
11. Do you plan to have a colonoscopy in the next five years? 
YES..............................................................................  1 
NO ............................................................................... 2 [GO TO 13] 
IF MY DOCTOR RECOMMENDS................................3 [GO TO 13] 
OTHER ___________________. .................................4  [GO TO 13] 
DON’T KNOW...............................................................8 [GO TO 13] 
REFUSED....................................................................  9  [GO TO 13] 
 
12. When do you plan to get your next colonoscopy? _________   
specify:___________   
  Month  /  year 
[Only read if they need help:] 
 
IN THE NEXT YEAR? ..................................................1 
IN 2 YEARS?................................................................2 
IN 3 YEARS?................................................................3 
IN 4 TO 5 YEARS?.......................................................4 
WHEN MY DOCTOR TELLS ME TO ...........................5 
DON’T KNOW...............................................................8 
  163 
REFUSED.....................................................................9 
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13. How LIKELY are you to get a colonoscopy in the next five years? 
 
Extremely likely ........................1 
Somewhat likely .......................2 
Neither likely nor unlikely .........3 
Somewhat unlikely ...................4  
Extremely unlikely ....................5 
DON’T KNOW..........................8  
REFUSED................................9  
 
14. The following questions have to do with whether YOU think your colorectal 
cancer may come back, either as a recurrence of the same cancer or as a new 
colorectal cancer.   
 
Assuming you get colonoscopies at regular intervals, what do you think is your 
chance of getting cancer in your colon or rectum again in your lifetime?  
 
No chance................................1 
Slight chance ...........................2 
Moderate chance .....................3 
High chance.............................4 
Certain to get it.........................5 
DON’T KNOW..........................8 
REFUSED................................9 
 
15. Assuming you do NOT get colonoscopies at regular intervals, what do you 
think is your chance of getting cancer in your colon or rectum again in your 
lifetime? 
 
No chance................................1 
Slight chance ...........................2 
Moderate chance .....................3 
High chance.............................4 
Certain to get it.........................5 
DON’T KNOW..........................8 
REFUSED................................9 
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The next two questions are about what people have told you about colonoscopies. 
 
30. Since your surgery for colorectal cancer, have any of your doctors 
recommended that you have a colonoscopy? 
 
YES...........................  1   
NO ............................ 2  [GO TO 34] 
DON’T KNOW............8  [GO TO 34] 
REFUSED................. 9   [GO TO 34] 
 
31. For each doctor recommending, please get specialty (or name, if no specialty)  
 
Specialty             Name (if don’t remember)     Was this your primary care  
                                                                          doctor? 
                                                                          Yes      No      DK     REFUSED 
 
__________      ______________                      1         2        8         9 
 
__________      ______________                      1         2        8         9 
 
__________      ______________                      1         2        8         9 
 
__________      ______________                      1         2        8         9 
 
 
[If not noted above]  Did your primary care doctor recommend that you have a 
colonoscopy? 
 
[If YES, please enter above]  
 
[No questions 32 and 33  anymore.  Question 32 is now part of 31 (PCP)] 
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34. Since you had surgery for your colorectal cancer, has any OTHER health care 
provider (such as a nurse) ever mentioned to you that you should get regular 
colonoscopies after you get treated for colorectal cancer? 
 
YES............................1 profession 
______________________________________ 
NO ............................ 2  (e.g., nurse) 
DON’T KNOW............8 
REFUSED................. 9  
 
35. Since you had surgery for your colorectal cancer, has anyone other than a 
health care provider ever mentioned to you that you should get regular 
colonoscopies after you get treated for colorectal cancer? 
 
YES............................1 who? 
_____________________________________________ 
NO .............................2 (e.g., friend, family member, clergy) 
DON’T KNOW............8 
REFUSED................. 9  
 
This is the last question. 
 
36. How confident are you that you can get a colonoscopy when you are due? 
 
Extremely confident .................1 
Fairly confident.........................2 
Somewhat confident ................3 
A little confident........................4 
Not at all confident ...................5 
DON’T KNOW..........................8 
REFUSED............................... 9 
 
 
We are finished with the survey.  Thank you very much for your participation in this 
study!   
 
Time finished __________ 
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APPENDIX D.  Marginal effect of changes in predictors on the predicted probability 
of receiving a colonoscopy in 14 months in the national cohort 
Change from  to  Average change in 
probability of 
colonoscopy 
Rectal cancer Colon cancer 0.09 
No comorbidities Severe comorbidities -0.13 
Did not see primary care 
provider 
Saw a primary care provider 0.05 
Did not have adjuvant 
chemotherapy 
Had adjuvant chemotherapy 0.11 
HMO study center Northern California study center -0.17 
HMO study center Alabama study center 0.02 
HMO study center Los Angeles study center 0.11 
HMO study center North Carolina study center 0.20 
HMO study center VA study center 0.10 
   175 
APPENDIX E.  Comparison of results for different lengths of follow-up in the national 
cohort 
 Months of follow-up 
 14 
(Main 
analysis) 
13 13.5 14.5 > 12 months      
 
N 1893 2154 2079 1470 2401  
Coefficients       
Age ns – ns ns ns  
Male  ns ns ns ns ns  
Married ns ns ns ns ns  
Race       
Black race ns ns ns ns ns  
Hispanic race ns ns ns ns ns  
Other race + + + ns +  
Completed high school ns ns ns ns ns  
Stage       
Stage II ns ns ns ns –  
Stage III – – – – –  
Colon + + + + +  
Comorbidity level       
Mild comorbidities ns ns ns ns ns  
Moderate comorbidities ns ns ns ns ns  
Severe comorbidities – – – – –  
Saw a primary care provider + ns ns + ns  
Saw a medical oncologist + ns ns ns ns  
Had adjuvant chemotherapy + + + + +  
Study centers       
Northern California – – – – ns  
Alabama ns ns ns ns ns  
Los Angeles + + + + +  
North Carolina + + + + +  
VA ns + + + +  
Jointly significant constructs       
Race Y Y Y N Y  
Stage Y Y N Y Y  
Comorbidity level Y Y Y Y Y  
Study center Y Y Y Y Y  
 
Note:  The column of 14-month follow-up results shows results of the main analysis 
with 14 months of follow-up.  The direction of statistically significant coefficients from 
the main (14 mo.) analysis and the sensitivity analyses are marked as positive (+) or 
negative (–), and non-significant results are marked as ns.  Joint significance of 
constructs is noted as significant (Y) or not significant (N).  Results from sensitivity 
analyses that are different from those of the main analyses are marked with a 
shaded cell.   
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APPENDIX F.  Mean values of individual benefit and barrier items in the NC cohort. 
Health Belief N Mean (s.d.) 
Perceived benefits (1=strongly disagree, 5=strongly 
agree) 
  
Finding another CRC early will save your life. 220 4.76 (0.60) 
The treatment for CRC may not be as bad if the 
cancer is found early. 
221 4.79 (0.44) 
A colonoscopy will help find CRC early. 223 4.77 (0.54) 
A colonoscopy will decrease your chance of dying 
from CRC. 
222 4.60 (0.73) 
A colonoscopy will help you not worry as much about 
CRC. 
224 4.71 (0.57) 
Perceived barriers (1=strongly disagree, 5=strongly 
agree) 
  
You are afraid to have a colonoscopy because you 
might find out something is wrong. 
226 1.64 (1.11) 
A colonoscopy is embarrassing. 224 1.93 (1.28) 
You do not have the time to do a colonoscopy. 225 1.42 (0.70) 
The cost of a colonoscopy is too high. 209 2.10 (1.25) 
You do not need to do a  colonoscopy because you 
are cancer-free. 
223 1.42 (0.74) 
Having a colonoscopy is painful. 223 1.58 (0.84) 
Having to follow a special diet and take a laxative or 
enema would keep you from having a colonoscopy. 
225 1.48 (0.71) 
You are afraid to have a colonoscopy because of the 
possibility there may be bleeding or tearing of the 
colon. 
225 1.63 (0.83) 
Transportation problems would keep you from getting 
to the clinic where you would receive a colonoscopy. 
226 1.48 (0.71) 
Note: s.d. = standard deviation, CRC = colorectal cancer 
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APPENDIX H.  Timing of colonoscopy after surgery (paper 1) 
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